{ "instance": { "f10k2022_180lifesci.htm": { "axisCustom": 0, "axisStandard": 26, "baseTaxonomies": { "http://fasb.org/srt/2022": 4, "http://fasb.org/us-gaap/2022": 903, "http://xbrl.sec.gov/dei/2022": 37 }, "contextCount": 485, "dts": { "calculationLink": { "local": [ "atnf-20221231_cal.xml" ] }, "definitionLink": { "local": [ "atnf-20221231_def.xml" ] }, "inline": { "local": [ "f10k2022_180lifesci.htm" ] }, "labelLink": { "local": [ "atnf-20221231_lab.xml" ] }, "presentationLink": { "local": [ "atnf-20221231_pre.xml" ] }, "schema": { "local": [ "atnf-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 985, "entityCount": 1, "hidden": { "http://180lifesciences.com/20221231": 180, "http://fasb.org/us-gaap/2022": 118, "http://xbrl.sec.gov/dei/2022": 3, "total": 301 }, "keyCustom": 289, "keyStandard": 375, "memberCustom": 115, "memberStandard": 23, "nsprefix": "atnf", "nsuri": "http://180lifesciences.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://180lifesciences.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://180lifesciences.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Prepaid Expenses and Other Current Assets", "menuCat": "Notes", "order": "11", "role": "http://180lifesciences.com/role/PrepaidExpensesandOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Intangible Assets and Impairment of Long-Lived Assets", "menuCat": "Notes", "order": "12", "role": "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssets", "shortName": "Intangible Assets and Impairment of Long-Lived Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Accrued Expenses", "menuCat": "Notes", "order": "13", "role": "http://180lifesciences.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:AcruedIssuableEquityTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Accrued Issuable Equity", "menuCat": "Notes", "order": "14", "role": "http://180lifesciences.com/role/AccruedIssuableEquity", "shortName": "Accrued Issuable Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:AcruedIssuableEquityTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Derivative Liabilities", "menuCat": "Notes", "order": "15", "role": "http://180lifesciences.com/role/DerivativeLiabilities", "shortName": "Derivative Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:LoansPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Loans Payable", "menuCat": "Notes", "order": "16", "role": "http://180lifesciences.com/role/LoansPayable", "shortName": "Loans Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:LoansPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Convertible Notes Payable", "menuCat": "Notes", "order": "17", "role": "http://180lifesciences.com/role/ConvertibleNotesPayable", "shortName": "Convertible Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "18", "role": "http://180lifesciences.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "19", "role": "http://180lifesciences.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://180lifesciences.com/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "20", "role": "http://180lifesciences.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Related Parties", "menuCat": "Notes", "order": "21", "role": "http://180lifesciences.com/role/RelatedParties", "shortName": "Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "22", "role": "http://180lifesciences.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "23", "role": "http://180lifesciences.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "24", "role": "http://180lifesciences.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:ScheduleOfPrepaidExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "menuCat": "Tables", "order": "25", "role": "http://180lifesciences.com/role/PrepaidExpensesandOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:ScheduleOfPrepaidExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Intangible Assets and Impairment of Long-Lived Assets (Tables)", "menuCat": "Tables", "order": "26", "role": "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsTables", "shortName": "Intangible Assets and Impairment of Long-Lived Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Accrued Expenses (Tables)", "menuCat": "Tables", "order": "27", "role": "http://180lifesciences.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Accrued Issuable Equity (Tables)", "menuCat": "Tables", "order": "28", "role": "http://180lifesciences.com/role/AccruedIssuableEquityTables", "shortName": "Accrued Issuable Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtConversionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Derivative Liabilities (Tables)", "menuCat": "Tables", "order": "29", "role": "http://180lifesciences.com/role/DerivativeLiabilitiesTables", "shortName": "Derivative Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtConversionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:ScheduleOfLoansPayableActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Loans Payable (Tables)", "menuCat": "Tables", "order": "30", "role": "http://180lifesciences.com/role/LoansPayableTables", "shortName": "Loans Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:ScheduleOfLoansPayableActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Convertible Notes Payable (Tables)", "menuCat": "Tables", "order": "31", "role": "http://180lifesciences.com/role/ConvertibleNotesPayableTables", "shortName": "Convertible Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "32", "role": "http://180lifesciences.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Stockholders' Equity (Tables)", "menuCat": "Tables", "order": "33", "role": "http://180lifesciences.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "34", "role": "http://180lifesciences.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Business Organization and Nature of Operations (Details)", "menuCat": "Details", "order": "35", "role": "http://180lifesciences.com/role/BusinessOrganizationandNatureofOperationsDetails", "shortName": "Business Organization and Nature of Operations (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "atnf:AccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Going Concern and Management's Plans (Details)", "menuCat": "Details", "order": "36", "role": "http://180lifesciences.com/role/GoingConcernandManagementsPlansDetails", "shortName": "Going Concern and Management's Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "atnf:AccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:AssetsAndLiabilitiesExchangeRatesDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "37", "role": "http://180lifesciences.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:AssetsAndLiabilitiesExchangeRatesDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of anti dilutive common shares", "menuCat": "Details", "order": "38", "role": "http://180lifesciences.com/role/ScheduleofantidilutivecommonsharesTable", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of anti dilutive common shares", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "link:footnote", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherExpenses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "menuCat": "Details", "order": "39", "role": "http://180lifesciences.com/role/PrepaidExpensesandOtherCurrentAssetsDetails", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://180lifesciences.com/role/ConsolidatedIncomeStatement", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "atnf:ScheduleOfPrepaidExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "atnf:LitigationReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses", "menuCat": "Details", "order": "40", "role": "http://180lifesciences.com/role/ScheduleofprepaidexpensesTable", "shortName": "Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "atnf:ScheduleOfPrepaidExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "atnf:LitigationReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Intangible Assets and Impairment of Long-Lived Assets (Details)", "menuCat": "Details", "order": "41", "role": "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails", "shortName": "Intangible Assets and Impairment of Long-Lived Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Intangible Assets and Impairment of Long-Lived Assets (Details) - Schedule of intangible assets", "menuCat": "Details", "order": "42", "role": "http://180lifesciences.com/role/ScheduleofintangibleassetsTable", "shortName": "Intangible Assets and Impairment of Long-Lived Assets (Details) - Schedule of intangible assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Intangible Assets and Impairment of Long-Lived Assets (Details) - Schedule of future amortization related to intangible assets", "menuCat": "Details", "order": "43", "role": "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable", "shortName": "Intangible Assets and Impairment of Long-Lived Assets (Details) - Schedule of future amortization related to intangible assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c60", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Intangible Assets and Impairment of Long-Lived Assets (Details) - Schedule of goodwill activity", "menuCat": "Details", "order": "44", "role": "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable", "shortName": "Intangible Assets and Impairment of Long-Lived Assets (Details) - Schedule of goodwill activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c63", "decimals": "0", "lang": null, "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "atnf:RelatedPartyExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Accrued Expenses (Details)", "menuCat": "Details", "order": "45", "role": "http://180lifesciences.com/role/AccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "atnf:RelatedPartyExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "atnf:ConsultingFees", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Accrued Expenses (Details) - Schedule of accrued expenses", "menuCat": "Details", "order": "46", "role": "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable", "shortName": "Accrued Expenses (Details) - Schedule of accrued expenses", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "atnf:ConsultingFees", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c96", "decimals": "0", "first": true, "lang": null, "name": "atnf:AggregateValueOfCommonSharesOnMonthlyBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Accrued Issuable Equity (Details)", "menuCat": "Details", "order": "47", "role": "http://180lifesciences.com/role/AccruedIssuableEquityDetails", "shortName": "Accrued Issuable Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c96", "decimals": "0", "first": true, "lang": null, "name": "atnf:AggregateValueOfCommonSharesOnMonthlyBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c25", "decimals": "0", "first": true, "lang": null, "name": "atnf:AccruedIssuableEquityBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Accrued Issuable Equity (Details) - Schedule of accrued issuable equity activity", "menuCat": "Details", "order": "48", "role": "http://180lifesciences.com/role/ScheduleofaccruedissuableequityactivityTable", "shortName": "Accrued Issuable Equity (Details) - Schedule of accrued issuable equity activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c25", "decimals": "0", "first": true, "lang": null, "name": "atnf:AccruedIssuableEquityBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Derivative Liabilities (Details)", "menuCat": "Details", "order": "49", "role": "http://180lifesciences.com/role/DerivativeLiabilitiesDetails", "shortName": "Derivative Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://180lifesciences.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtConversionsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "atnf:DerivativeLiabilityBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Derivative Liabilities (Details) - Schedule of derivative liabilities", "menuCat": "Details", "order": "50", "role": "http://180lifesciences.com/role/ScheduleofderivativeliabilitiesTable", "shortName": "Derivative Liabilities (Details) - Schedule of derivative liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtConversionsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "atnf:DerivativeLiabilityBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c25", "decimals": "0", "first": true, "lang": null, "name": "atnf:DerivativeLiabilitie", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Derivative Liabilities (Details) - Schedule of fair value of Level 3 derivative liabilities (except the Public Special Purpose Acquisition Companies (\u201cSPAC\u201d) warrants as defined below, which are Level 1 derivative liabilities that are measured at fair value on a recurring basis", "menuCat": "Details", "order": "51", "role": "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable", "shortName": "Derivative Liabilities (Details) - Schedule of fair value of Level 3 derivative liabilities (except the Public Special Purpose Acquisition Companies (\u201cSPAC\u201d) warrants as defined below, which are Level 1 derivative liabilities that are measured at fair value on a recurring basis", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c25", "decimals": "0", "first": true, "lang": null, "name": "atnf:DerivativeLiabilitie", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c114", "decimals": "4", "first": true, "lang": null, "name": "atnf:FairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Derivative Liabilities (Details) - Schedule of option pricing models", "menuCat": "Details", "order": "52", "role": "http://180lifesciences.com/role/ScheduleofoptionpricingmodelsTable", "shortName": "Derivative Liabilities (Details) - Schedule of option pricing models", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c114", "decimals": "4", "first": true, "lang": null, "name": "atnf:FairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "atnf:ScheduleOfWarrantActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "atnf:NumberOfWarrantsOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Derivative Liabilities (Details) - Schedule of warrant activity", "menuCat": "Details", "order": "53", "role": "http://180lifesciences.com/role/ScheduleofwarrantactivityTable", "shortName": "Derivative Liabilities (Details) - Schedule of warrant activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "atnf:ScheduleOfWarrantActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c25", "decimals": "INF", "lang": null, "name": "atnf:NumberOfWarrantsOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "atnf:ScheduleOfOutstandingAndExercisableWarrantsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Derivative Liabilities (Details) - Schedule of outstanding and exercisable warrants", "menuCat": "Details", "order": "54", "role": "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable", "shortName": "Derivative Liabilities (Details) - Schedule of outstanding and exercisable warrants", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "atnf:ScheduleOfOutstandingAndExercisableWarrantsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "atnf:AdjustedAPortionLoanAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Loans Payable (Details)", "menuCat": "Details", "order": "55", "role": "http://180lifesciences.com/role/LoansPayableDetails", "shortName": "Loans Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "atnf:AdjustedAPortionLoanAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "atnf:ScheduleOfLoansPayableActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentAnnualPrincipalPayment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Loans Payable (Details) - Schedule of loans payable activity", "menuCat": "Details", "order": "56", "role": "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable", "shortName": "Loans Payable (Details) - Schedule of loans payable activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c25", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentAnnualPrincipalPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "atnf:LoansPayableCurrentPortions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Loans Payable (Details) - Schedule of loans payable of current portion", "menuCat": "Details", "order": "57", "role": "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable", "shortName": "Loans Payable (Details) - Schedule of loans payable of current portion", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "atnf:LoansPayableCurrentPortions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "atnf:ScheduleOfNoncurrentLoansPayableTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "atnf:LoansPayableNonCurrentPortions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Loans Payable (Details) - Schedule of non-current loans payable", "menuCat": "Details", "order": "58", "role": "http://180lifesciences.com/role/ScheduleofnoncurrentloanspayableTable", "shortName": "Loans Payable (Details) - Schedule of non-current loans payable", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "atnf:ScheduleOfNoncurrentLoansPayableTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "atnf:LoansPayableNonCurrentPortions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "atnf:RelatedPartyLoans", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Loans Payable (Details) - Schedule of related party loans payable", "menuCat": "Details", "order": "59", "role": "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable", "shortName": "Loans Payable (Details) - Schedule of related party loans payable", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "atnf:RelatedPartyLoans", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c21", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity", "menuCat": "Statements", "order": "6", "role": "http://180lifesciences.com/role/ShareholdersEquityType2or3", "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c21", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "atnf:InterestExpenseOnConvertibleDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Convertible Notes Payable (Details)", "menuCat": "Details", "order": "60", "role": "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "shortName": "Convertible Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "atnf:InterestExpenseOnConvertibleDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c308", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentIssuanceDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Convertible Notes Payable (Details) - Schedule of convertible notes payable activity", "menuCat": "Details", "order": "61", "role": "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable", "shortName": "Convertible Notes Payable (Details) - Schedule of convertible notes payable activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c308", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentIssuanceDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "atnf:ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c323", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtConversionConvertedInstrumentIssuanceDateDayMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Convertible Notes Payable (Details) - Schedule of convertible notes payable related parties", "menuCat": "Details", "order": "62", "role": "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable", "shortName": "Convertible Notes Payable (Details) - Schedule of convertible notes payable related parties", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "atnf:ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c323", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtConversionConvertedInstrumentIssuanceDateDayMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "atnf:ConvertiblePromissoryNotesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c335", "decimals": "0", "first": true, "lang": null, "name": "atnf:PrincipalBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Convertible Notes Payable (Details) - Schedule of convertible promissory notes", "menuCat": "Details", "order": "63", "role": "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable", "shortName": "Convertible Notes Payable (Details) - Schedule of convertible promissory notes", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "atnf:ConvertiblePromissoryNotesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c335", "decimals": "0", "first": true, "lang": null, "name": "atnf:PrincipalBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "atnf:ScheduleOfSecuredConvertiblePromissoryNotesElectedToConvertPrincipalTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c344", "decimals": "0", "first": true, "lang": null, "name": "atnf:PrincipalBalanceConverted1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Convertible Notes Payable (Details) - Schedule of secured convertible promissory notes", "menuCat": "Details", "order": "64", "role": "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable", "shortName": "Convertible Notes Payable (Details) - Schedule of secured convertible promissory notes", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "atnf:ScheduleOfSecuredConvertiblePromissoryNotesElectedToConvertPrincipalTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c344", "decimals": "0", "first": true, "lang": null, "name": "atnf:PrincipalBalanceConverted1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c348", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProductLiabilityContingencyLossExposureInExcessOfAccrualBestEstimate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "65", "role": "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c348", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProductLiabilityContingencyLossExposureInExcessOfAccrualBestEstimate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c404", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:ConsultingFeePaymentMilestoneDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Commitments and Contingencies (Details) - Schedule of make the following payments to oxford", "menuCat": "Details", "order": "66", "role": "http://180lifesciences.com/role/ScheduleofmakethefollowingpaymentstooxfordTable", "shortName": "Commitments and Contingencies (Details) - Schedule of make the following payments to oxford", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c404", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:ConsultingFeePaymentMilestoneDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Stockholders' Equity (Details)", "menuCat": "Details", "order": "67", "role": "http://180lifesciences.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c427", "decimals": null, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Stockholders' Equity (Details) - Schedule of restricted stock shares granted and outstanding", "menuCat": "Details", "order": "68", "role": "http://180lifesciences.com/role/ScheduleofrestrictedstocksharesgrantedandoutstandingTable", "shortName": "Stockholders' Equity (Details) - Schedule of restricted stock shares granted and outstanding", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "atnf:SpecialVotingSharesActivityTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "atnf:SpecialVotingShareActivity", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Stockholders' Equity (Details) - Schedule of special voting shares activity", "menuCat": "Details", "order": "69", "role": "http://180lifesciences.com/role/ScheduleofspecialvotingsharesactivityTable", "shortName": "Stockholders' Equity (Details) - Schedule of special voting shares activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "atnf:SpecialVotingSharesActivityTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c25", "decimals": "INF", "lang": null, "name": "atnf:SpecialVotingShareActivity", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://180lifesciences.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Stockholders' Equity (Details) - Schedule of option activity", "menuCat": "Details", "order": "70", "role": "http://180lifesciences.com/role/ScheduleofoptionactivityTable", "shortName": "Stockholders' Equity (Details) - Schedule of option activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c25", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Stockholders' Equity (Details) - Schedule of outstanding and exercisable stock options", "menuCat": "Details", "order": "71", "role": "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablestockoptionsTable", "shortName": "Stockholders' Equity (Details) - Schedule of outstanding and exercisable stock options", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Stockholders' Equity (Details) - Schedule of estimated using the black scholes valuation method assumptions", "menuCat": "Details", "order": "72", "role": "http://180lifesciences.com/role/ScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsTable", "shortName": "Stockholders' Equity (Details) - Schedule of estimated using the black scholes valuation method assumptions", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "73", "role": "http://180lifesciences.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - Income Taxes (Details) - Schedule of income tax domestic and international components", "menuCat": "Details", "order": "74", "role": "http://180lifesciences.com/role/ScheduleofincometaxdomesticandinternationalcomponentsTable", "shortName": "Income Taxes (Details) - Schedule of income tax domestic and international components", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "atnf:ScheduleOfIncomeTaxBenefitsProvisionTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "074 - Disclosure - Income Taxes (Details) - Schedule of income tax benefits provision", "menuCat": "Details", "order": "75", "role": "http://180lifesciences.com/role/ScheduleofincometaxbenefitsprovisionTable", "shortName": "Income Taxes (Details) - Schedule of income tax benefits provision", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "atnf:ScheduleOfIncomeTaxBenefitsProvisionTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "075 - Disclosure - Income Taxes (Details) - Schedule of united states federal statutory rate", "menuCat": "Details", "order": "76", "role": "http://180lifesciences.com/role/ScheduleofunitedstatesfederalstatutoryrateTable", "shortName": "Income Taxes (Details) - Schedule of united states federal statutory rate", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "076 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities", "menuCat": "Details", "order": "77", "role": "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable", "shortName": "Income Taxes (Details) - Schedule of deferred tax assets and liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "atnf:DeferredTaxAssetsBeginning", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "077 - Disclosure - Income Taxes (Details) - Schedule of valuation deferred tax assets", "menuCat": "Details", "order": "78", "role": "http://180lifesciences.com/role/ScheduleofvaluationdeferredtaxassetsTable", "shortName": "Income Taxes (Details) - Schedule of valuation deferred tax assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "atnf:DeferredTaxAssetsBeginning", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "atnf:AccruedExpensesRelatedParties", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "078 - Disclosure - Related Parties (Details)", "menuCat": "Details", "order": "79", "role": "http://180lifesciences.com/role/RelatedPartiesDetails", "shortName": "Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c8", "decimals": "0", "lang": null, "name": "atnf:AccruedExpenseRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Business Organization and Nature of Operations", "menuCat": "Notes", "order": "8", "role": "http://180lifesciences.com/role/BusinessOrganizationandNatureofOperations", "shortName": "Business Organization and Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "link:footnote", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherExpenses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "079 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "80", "role": "http://180lifesciences.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c481", "decimals": "0", "lang": null, "name": "us-gaap:ExcessStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:GoingConcernAndManagementsPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Going Concern and Management's Plans", "menuCat": "Notes", "order": "9", "role": "http://180lifesciences.com/role/GoingConcernandManagementsPlans", "shortName": "Going Concern and Management's Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_180lifesci.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "atnf:GoingConcernAndManagementsPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 147, "tag": { "atnf_AGPWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AGPWarrants Member", "terseLabel": "AGP Warrant [Member]", "verboseLabel": "AGP Warrants [Member]" } } }, "localname": "AGPWarrantsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "atnf_AccruedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount excluding accrued interest, of investment in debt security measured at amortized cost (held-to-maturity) on nonaccrual status.", "label": "Accrued Amount", "terseLabel": "Accrued amount" } } }, "localname": "AccruedAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AccruedExpenseRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Expense Related Parties", "label": "Accrued Expense Related Parties", "terseLabel": "Accrued expenses - related parties" } } }, "localname": "AccruedExpenseRelatedParties", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AccruedExpensesRelatedParties": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of accrued expenses - related parties.", "label": "Accrued Expenses Related Parties", "terseLabel": "Accrued expenses - related parties" } } }, "localname": "AccruedExpensesRelatedParties", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet", "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AccruedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued interest.", "label": "Accrued Interest", "terseLabel": "Accrued interest" } } }, "localname": "AccruedInterest", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AccruedInterestConvertedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued interest converted to Equity.", "label": "Accrued Interest Converted Amount", "terseLabel": "Aggregate accrued interest" } } }, "localname": "AccruedInterestConvertedAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AccruedInterestOnConvertibleDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued interest on convertible debt.", "label": "Accrued Interest On Convertible Debt", "terseLabel": "Accrued interest on convertible debt" } } }, "localname": "AccruedInterestOnConvertibleDebt", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AccruedInterests": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued interest.", "label": "Accrued Interests", "terseLabel": "Accrued interest" } } }, "localname": "AccruedInterests", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "atnf_AccruedIssuableEquityBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued issuable equity.", "label": "Accrued Issuable Equity Balance", "periodEndLabel": "Balance at Ending", "periodStartLabel": "Balance at beginning" } } }, "localname": "AccruedIssuableEquityBalance", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofaccruedissuableequityactivityTable" ], "xbrltype": "monetaryItemType" }, "atnf_AccruedIssuableEquityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Issuable Equity.", "label": "Accrued Issuable Equity Policy Text Block", "terseLabel": "Accrued Issuable Equity" } } }, "localname": "AccruedIssuableEquityPolicyTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "atnf_AccruedIssuableEquityRelatedToServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued issuable equity related to services.", "label": "Accrued Issuable Equity Related To Services", "terseLabel": "Accrued issuable equity related to services" } } }, "localname": "AccruedIssuableEquityRelatedToServices", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/AccruedIssuableEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AccruedIssuableEquitys": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued Issuable Equitys", "negatedLabel": "Accrued issuable equity" } } }, "localname": "AccruedIssuableEquitys", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_AccruedLiabilities": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accrued Liabilities", "totalLabel": "Total" } } }, "localname": "AccruedLiabilities", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable" ], "xbrltype": "monetaryItemType" }, "atnf_AccumulatedDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "AccumulatedDeficit", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/GoingConcernandManagementsPlansDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AcruedIssuableEquityTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of accrued issuable equity text Block.", "label": "Acrued Issuable Equity Textblock", "terseLabel": "ACCRUED ISSUABLE EQUITY" } } }, "localname": "AcruedIssuableEquityTextblock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/AccruedIssuableEquity" ], "xbrltype": "textBlockItemType" }, "atnf_AcruedIssuableEquityTextblockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Issuable Equity [Abstract]" } } }, "localname": "AcruedIssuableEquityTextblockAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_AdditionalConsiderationAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional consideration agreement description", "label": "Additional Consideration Agreement Description", "terseLabel": "Additional consideration agreement, description" } } }, "localname": "AdditionalConsiderationAgreementDescription", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "atnf_AdditionalConsultingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional consulting percentage", "label": "Additional Consulting Percentage", "terseLabel": "Additional consulting percentage" } } }, "localname": "AdditionalConsultingPercentage", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "atnf_AdditionalSumOfAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional sum of amount", "label": "Additional Sum Of Amount", "terseLabel": "Additional sum of amount" } } }, "localname": "AdditionalSumOfAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AdjustedAPortionLoanAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of adjusted a portion loan amount", "label": "Adjusted APortion Loan Amount", "terseLabel": "Financed in loans payable" } } }, "localname": "AdjustedAPortionLoanAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AdjustmentsAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Adjustments Amount", "terseLabel": "Adjustments" } } }, "localname": "AdjustmentsAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "monetaryItemType" }, "atnf_AggregateCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value.", "label": "Aggregate Carrying Value", "terseLabel": "Aggregate carrying value" } } }, "localname": "AggregateCarryingValue", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AggregateGrossProceeds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate gross proceeds.", "label": "Aggregate Gross Proceeds", "terseLabel": "Aggregate gross proceeds" } } }, "localname": "AggregateGrossProceeds", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AggregateIssuanceDateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of aggregate issuance date fair value.", "label": "Aggregate Issuance Date Fair Value", "terseLabel": "Aggregate issuance date fair value" } } }, "localname": "AggregateIssuanceDateFairValue", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AggregateOfSharesOfCommonStockDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate of shares of common stock.", "label": "Aggregate Of Shares Of Common Stock Description", "terseLabel": "Aggregate of shares of common stock" } } }, "localname": "AggregateOfSharesOfCommonStockDescription", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "stringItemType" }, "atnf_AggregateOutstandingPrincipalOfConvertibleNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of aggregate outstanding principal of convertible notes.", "label": "Aggregate Outstanding Principal Of Convertible Notes", "terseLabel": "Aggregate outstanding principal of convertible notes" } } }, "localname": "AggregateOutstandingPrincipalOfConvertibleNotes", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AggregatePrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregate Principal Amount", "terseLabel": "Principal amount" } } }, "localname": "AggregatePrincipalAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AggregateShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Aggregate Share Of Common Stock", "terseLabel": "Aggregate shares of common stock (in Shares)" } } }, "localname": "AggregateShareOfCommonStock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "atnf_AggregateShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate shares.", "label": "Aggregate Shares", "terseLabel": "Aggregate shares (in Shares)" } } }, "localname": "AggregateShares", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "atnf_AggregateShares1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate shares.", "label": "Aggregate Shares1", "terseLabel": "Aggregate shares (in Shares)" } } }, "localname": "AggregateShares1", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "sharesItemType" }, "atnf_AggregateValueOfCommonSharesAtEndOfEachQuarter": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of common shares at end of each quarter.", "label": "Aggregate Value Of Common Shares At End Of Each Quarter", "terseLabel": "Aggregate value of common shares at end of each quarter" } } }, "localname": "AggregateValueOfCommonSharesAtEndOfEachQuarter", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/AccruedIssuableEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AggregateValueOfCommonSharesOnMonthlyBasis": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of common shares on monthly basis.", "label": "Aggregate Value Of Common Shares On Monthly Basis", "terseLabel": "Aggregate value of common shares on monthly basis" } } }, "localname": "AggregateValueOfCommonSharesOnMonthlyBasis", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/AccruedIssuableEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AgreementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement Period", "terseLabel": "Agreement period" } } }, "localname": "AgreementPeriod", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "atnf_AllocatedToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allocated to common stock.", "label": "Allocated To Common Stock", "terseLabel": "Allocated to common stock" } } }, "localname": "AllocatedToCommonStock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AllocatedToWarrantLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allocated to warrant liabilities.", "label": "Allocated To Warrant Liabilities", "terseLabel": "Allocated to warrant liabilities" } } }, "localname": "AllocatedToWarrantLiabilities", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_AlphaCapitalConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Alpha Capital Convertible Promissory Note Member", "terseLabel": "Alpha Capital Convertible Promissory Note [Member]" } } }, "localname": "AlphaCapitalConvertiblePromissoryNoteMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable", "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable" ], "xbrltype": "domainItemType" }, "atnf_AlphaCapitalNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Alpha Capital Note Member", "terseLabel": "Alpha Capital Note [Member]" } } }, "localname": "AlphaCapitalNoteMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "atnf_AlphaConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Alpha Convertible Promissory Note Member", "terseLabel": "Alpha Convertible Promissory Note [Member]" } } }, "localname": "AlphaConvertiblePromissoryNoteMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "atnf_AlphaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Alpha Member", "terseLabel": "Alpha [Member]" } } }, "localname": "AlphaMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable" ], "xbrltype": "domainItemType" }, "atnf_AlphaWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Alpha Warrant Member", "terseLabel": "Alpha Warrant [Member]" } } }, "localname": "AlphaWarrantMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "atnf_AmoritizationOfStockOptions": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization of stock options.", "label": "Amoritization Of Stock Options", "terseLabel": "Amortization of stock options and restricted stock units" } } }, "localname": "AmoritizationOfStockOptions", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_AssetsAndLiabilitiesExchangeRatesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets And Liabilities Exchange Rates Description", "terseLabel": "Foreign currency translation description" } } }, "localname": "AssetsAndLiabilitiesExchangeRatesDescription", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "atnf_BBLSLoanPayableIssuedNonCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BBLSLoan Payable Issued Non Current Member", "terseLabel": "BBLS loan payable issued June 10, 2020 [Member]" } } }, "localname": "BBLSLoanPayableIssuedNonCurrentMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofnoncurrentloanspayableTable" ], "xbrltype": "domainItemType" }, "atnf_BadDebtExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Bad debt expense", "label": "Bad Debt Expense", "terseLabel": "Bad debt expense" } } }, "localname": "BadDebtExpense", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_BeneficialOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Beneficial Ownership", "terseLabel": "Beneficial ownership" } } }, "localname": "BeneficialOwnership", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "atnf_BounceBackLoanScheme": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of bounce back loan scheme.", "label": "Bounce Back Loan Scheme", "terseLabel": "Bounce back loan scheme" } } }, "localname": "BounceBackLoanScheme", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_BounceBackLoanSchemeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bounce Back Loan Scheme Member", "terseLabel": "Bounce Back Loan Scheme [Member]" } } }, "localname": "BounceBackLoanSchemeMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails", "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "domainItemType" }, "atnf_BridgeNoteConversionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bridge Note Conversions Member", "terseLabel": "Conversions [Member]" } } }, "localname": "BridgeNoteConversionsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "atnf_BridgeNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bridge Note One Member", "terseLabel": "Bridge Note One [Member]" } } }, "localname": "BridgeNoteOneMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable" ], "xbrltype": "domainItemType" }, "atnf_BridgeNotesInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of bridge notes interest rate.", "label": "Bridge Notes Interest Rate", "terseLabel": "Bridge notes interest rate" } } }, "localname": "BridgeNotesInterestRate", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "percentItemType" }, "atnf_BusinessCombinationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination Member", "terseLabel": "Business Combination [Member]" } } }, "localname": "BusinessCombinationMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "atnf_CBRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CBRMember", "label": "CBRMember", "terseLabel": "CBR [Member]" } } }, "localname": "CBRMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_CBRPharmaGoodwillMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CBRPharma Goodwill Member", "terseLabel": "CBR Pharma Goodwill [Member]" } } }, "localname": "CBRPharmaGoodwillMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable" ], "xbrltype": "domainItemType" }, "atnf_CBRPharmaIPRDAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CBRPharma IPRDAssets Member", "terseLabel": "CBR Pharma IP R&D Assets [Member]" } } }, "localname": "CBRPharmaIPRDAssetsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable" ], "xbrltype": "domainItemType" }, "atnf_CBRPharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CBRPharma Member", "terseLabel": "CBR Pharma [Member]" } } }, "localname": "CBRPharmaMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails" ], "xbrltype": "domainItemType" }, "atnf_CEOsAnnualBaseSalary": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "CEOs annual base salary", "label": "CEOs Annual Base Salary", "terseLabel": "CEOs annual base salary" } } }, "localname": "CEOsAnnualBaseSalary", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_CanadianFederalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Canadian Federal", "label": "Canadian Federal Member", "terseLabel": "Canadian Federal [Member}" } } }, "localname": "CanadianFederalMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "atnf_ChangeInFairValueOfAccruedIssuableEquity": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 8.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change In Fair Value Of Accrued Issuable Equity", "terseLabel": "Change in fair value of accrued issuable equity" } } }, "localname": "ChangeInFairValueOfAccruedIssuableEquity", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow", "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "atnf_ChangeInFairValueOfDerivativeLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of derivative liabilities.", "label": "Change In Fair Value Of Derivative Liabilities", "terseLabel": "Change in fair value of derivative liabilities" } } }, "localname": "ChangeInFairValueOfDerivativeLiabilities", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofderivativeliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "atnf_ChangeInFairValuesOfDerivativeLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of derivative liabilities.", "label": "Change In Fair Values Of Derivative Liabilities", "terseLabel": "Change in fair value of derivative liabilities" } } }, "localname": "ChangeInFairValuesOfDerivativeLiabilities", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "atnf_ChangeInValuationPursuantToTheTaxProvision": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change In Valuation Pursuant To The Tax Provision", "negatedLabel": "Change in valuation pursuant to the tax provision" } } }, "localname": "ChangeInValuationPursuantToTheTaxProvision", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofvaluationdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "atnf_ChiefOperatingOfficerChiefBusinessOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chief Operating Officer Chief Business Officer Member", "terseLabel": "Chief Operating Officer/Chief Business Officer [Member]" } } }, "localname": "ChiefOperatingOfficerChiefBusinessOfficerMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_ClassOfWarrantOrRightExercisesPriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercises Price Of Warrants Or Rights", "terseLabel": "Exercise price per share (in Dollars per share)", "verboseLabel": "Class Of Warrant Or Right Exercises Price Of Warrants Or Rights (in Dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisesPriceOfWarrantsOrRights", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "atnf_CommitmentsCombinedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Commitments combined amount", "label": "Commitments Combined Amount", "terseLabel": "Commitments combined amount" } } }, "localname": "CommitmentsCombinedAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_CommitmentsandContingenciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "atnf_CommitmentsandContingenciesDetailsScheduleofmakethefollowingpaymentstooxfordLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) - Schedule of make the following payments to oxford [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsScheduleofmakethefollowingpaymentstooxfordLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofmakethefollowingpaymentstooxfordTable" ], "xbrltype": "stringItemType" }, "atnf_CommitmentsandContingenciesDetailsScheduleofmakethefollowingpaymentstooxfordTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) - Schedule of make the following payments to oxford [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsScheduleofmakethefollowingpaymentstooxfordTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofmakethefollowingpaymentstooxfordTable" ], "xbrltype": "stringItemType" }, "atnf_CommitmentsandContingenciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "atnf_CommonStockExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock exercise price.", "label": "Common Stock Exercise Price", "terseLabel": "Common stock exercise price (in Dollars per share)" } } }, "localname": "CommonStockExercisePrice", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "perShareItemType" }, "atnf_CommonStockIssuedForServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Issued For Services Member", "terseLabel": "Common Stock Issued for Services [Member]" } } }, "localname": "CommonStockIssuedForServicesMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "atnf_CommonStockIssuedUponConversionOfKBLDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Common Stock Issued Upon Conversion Of KBLDebt", "terseLabel": "Common stock issued upon conversion of KBL debt" } } }, "localname": "CommonStockIssuedUponConversionOfKBLDebt", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_CommonStockTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock term.", "label": "Common Stock Term", "terseLabel": "Common stock term" } } }, "localname": "CommonStockTerm", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "atnf_CommonStockToEarlyBirdValued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common Stock To Early Bird Valued", "terseLabel": "Common stock to EarlyBird valued" } } }, "localname": "CommonStockToEarlyBirdValued", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_CommonStocksEquivalentsSharesSpecialVotingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of common stocks equivalents shares special voting shares.", "label": "Common Stocks Equivalents Shares Special Voting Shares", "terseLabel": "Special voting shares (in Shares)" } } }, "localname": "CommonStocksEquivalentsSharesSpecialVotingShares", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "atnf_ConsolidatedGoodwillMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Goodwill Member", "terseLabel": "Consolidated Goodwill [Member]" } } }, "localname": "ConsolidatedGoodwillMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable" ], "xbrltype": "domainItemType" }, "atnf_ConsolidatedIPRDAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated IPRDAssets Member", "terseLabel": "Consolidated IP R&D Assets [Member]" } } }, "localname": "ConsolidatedIPRDAssetsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable" ], "xbrltype": "domainItemType" }, "atnf_ConsultantFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Consultant Fee", "terseLabel": "Consultant fee (in Euro)" } } }, "localname": "ConsultantFee", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_ConsultantsAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consultants amount", "label": "Consultants Amount", "terseLabel": "Consultants amount" } } }, "localname": "ConsultantsAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_ConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreement Member", "terseLabel": "Consulting Agreement [Member]" } } }, "localname": "ConsultingAgreementMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_ConsultingFeePaymentMilestoneDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A description of consulting fee payment milestone", "label": "Consulting Fee Payment Milestone Description", "terseLabel": "Milestone description" } } }, "localname": "ConsultingFeePaymentMilestoneDescription", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofmakethefollowingpaymentstooxfordTable" ], "xbrltype": "stringItemType" }, "atnf_ConsultingFees": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable": { "order": 1.0, "parentTag": "atnf_AccruedLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of consulting fees.", "label": "Consulting Fees", "terseLabel": "Consulting fees" } } }, "localname": "ConsultingFees", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable" ], "xbrltype": "monetaryItemType" }, "atnf_ConsultingServicesPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consulting services payable.", "label": "Consulting Services Payable", "terseLabel": "Consulting services payable" } } }, "localname": "ConsultingServicesPayable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_ConversionPriceOfConvertibleDebt": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion price of convertible debt.", "label": "Conversion Price Of Convertible Debt", "terseLabel": "Conversion price of convertible debt (in Dollars per share)" } } }, "localname": "ConversionPriceOfConvertibleDebt", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "perShareItemType" }, "atnf_ConvertedIntoCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Converted Into Common Stock", "terseLabel": "Converted into common stock (in Shares)" } } }, "localname": "ConvertedIntoCommonStock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "sharesItemType" }, "atnf_ConvertibleNotesPayableDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable (Details) [Line Items]" } } }, "localname": "ConvertibleNotesPayableDetailsLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "stringItemType" }, "atnf_ConvertibleNotesPayableDetailsScheduleofconvertiblenotespayableactivityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable (Details) - Schedule of convertible notes payable activity [Line Items]" } } }, "localname": "ConvertibleNotesPayableDetailsScheduleofconvertiblenotespayableactivityLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable" ], "xbrltype": "stringItemType" }, "atnf_ConvertibleNotesPayableDetailsScheduleofconvertiblenotespayableactivityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable (Details) - Schedule of convertible notes payable activity [Table]" } } }, "localname": "ConvertibleNotesPayableDetailsScheduleofconvertiblenotespayableactivityTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable" ], "xbrltype": "stringItemType" }, "atnf_ConvertibleNotesPayableDetailsScheduleofconvertiblenotespayablerelatedpartiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable (Details) - Schedule of convertible notes payable related parties [Line Items]" } } }, "localname": "ConvertibleNotesPayableDetailsScheduleofconvertiblenotespayablerelatedpartiesLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "stringItemType" }, "atnf_ConvertibleNotesPayableDetailsScheduleofconvertiblenotespayablerelatedpartiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable (Details) - Schedule of convertible notes payable related parties [Table]" } } }, "localname": "ConvertibleNotesPayableDetailsScheduleofconvertiblenotespayablerelatedpartiesTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "stringItemType" }, "atnf_ConvertibleNotesPayableDetailsScheduleofconvertiblepromissorynotesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable (Details) - Schedule of convertible promissory notes [Line Items]" } } }, "localname": "ConvertibleNotesPayableDetailsScheduleofconvertiblepromissorynotesLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable" ], "xbrltype": "stringItemType" }, "atnf_ConvertibleNotesPayableDetailsScheduleofconvertiblepromissorynotesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable (Details) - Schedule of convertible promissory notes [Table]" } } }, "localname": "ConvertibleNotesPayableDetailsScheduleofconvertiblepromissorynotesTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable" ], "xbrltype": "stringItemType" }, "atnf_ConvertibleNotesPayableDetailsScheduleofsecuredconvertiblepromissorynotesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable (Details) - Schedule of secured convertible promissory notes [Line Items]" } } }, "localname": "ConvertibleNotesPayableDetailsScheduleofsecuredconvertiblepromissorynotesLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable" ], "xbrltype": "stringItemType" }, "atnf_ConvertibleNotesPayableDetailsScheduleofsecuredconvertiblepromissorynotesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable (Details) - Schedule of secured convertible promissory notes [Table]" } } }, "localname": "ConvertibleNotesPayableDetailsScheduleofsecuredconvertiblepromissorynotesTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable" ], "xbrltype": "stringItemType" }, "atnf_ConvertibleNotesPayableDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable (Details) [Table]" } } }, "localname": "ConvertibleNotesPayableDetailsTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "stringItemType" }, "atnf_ConvertiblePromissoryNoteDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Promissory Note Description", "terseLabel": "Convertible promissory note, description" } } }, "localname": "ConvertiblePromissoryNoteDescription", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "stringItemType" }, "atnf_ConvertiblePromissoryNotesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Notes Table Text Block.", "label": "Convertible Promissory Notes Table Text Block", "terseLabel": "Schedule of convertible promissory notes" } } }, "localname": "ConvertiblePromissoryNotesTableTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "atnf_CurrentPortionOfPPPLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Current portion of PPP loans .", "label": "Current Portion Of PPPLoan", "terseLabel": "Less: Current portions of BBLS/PPP loans, respectively (see above)" } } }, "localname": "CurrentPortionOfPPPLoan", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofnoncurrentloanspayableTable" ], "xbrltype": "monetaryItemType" }, "atnf_DebtAdditionalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt Additional Amount", "terseLabel": "Additional amount" } } }, "localname": "DebtAdditionalAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_DebtConversionConvertedToEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of principal converted to equity during the period.", "label": "Debt Conversion Converted To Equity", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtConversionConvertedToEquity", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_DebtConversionInterestAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Conversion Interest means the percentage interest determined by a formula, where the (i) numerator is equal to the Conversion Amount, and the (ii) denominator is equal to the Conversion Value in effect at the time of such conversion.", "label": "Debt Conversion Interest Amount", "terseLabel": "Interest Converted" } } }, "localname": "DebtConversionInterestAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "atnf_DebtDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt discount.", "label": "Debt Discount", "terseLabel": "Debt discount" } } }, "localname": "DebtDiscount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_DebtDiscountBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt Discount Balance", "terseLabel": "Debt Discount, Balance at Ending" } } }, "localname": "DebtDiscountBalance", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "atnf_DebtDiscountImpactOfConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt Discount Impact Of Conversion", "terseLabel": "Debt Discount, Impact of conversion" } } }, "localname": "DebtDiscountImpactOfConversion", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "atnf_DebtDiscountImpactOfExtinguishment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt Discount Impact Of Extinguishment", "terseLabel": "Debt Discount, Impact of extinguishment" } } }, "localname": "DebtDiscountImpactOfExtinguishment", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "atnf_DebtIssued": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Debt Issued", "terseLabel": "Debt Issued" } } }, "localname": "DebtIssued", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "monetaryItemType" }, "atnf_DebtPrincipalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt Principal Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtPrincipalAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_DebtTotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Total Member", "terseLabel": "Debt total [Member]" } } }, "localname": "DebtTotalMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "atnf_December2022CommonWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 2022 Common Warrants Member.", "label": "December2022 Common Warrants Member", "terseLabel": "December 2022 Common Warrants [Member]" } } }, "localname": "December2022CommonWarrantsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "atnf_DecemberTwentyTwoOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December Twenty Two Offering Member.", "label": "December Twenty Two Offering Member", "terseLabel": "December Twenty Two Offering Member" } } }, "localname": "DecemberTwentyTwoOfferingMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "atnf_DecemberTwentyTwoPreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December Twenty Two Pre Funded Warrants Member.", "label": "December Twenty Two Pre Funded Warrants Member", "terseLabel": "December Twenty Two Pre Funded Warrants Member" } } }, "localname": "DecemberTwentyTwoPreFundedWarrantsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "atnf_DeemedDividendBeneficialConversionFeatureOnSeriesAConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "DeemedDividendBeneficialConversionFeatureOnSeriesAConvertiblePreferredStock", "label": "Deemed Dividend Beneficial Conversion Feature On Series AConvertible Preferred Stock", "terseLabel": "Common stock issued in connection with repayment of related party loans and convertible notes" } } }, "localname": "DeemedDividendBeneficialConversionFeatureOnSeriesAConvertiblePreferredStock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_DeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Abstract", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsAbstract", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "atnf_DeferredTaxAssetsAccruedCompensationNotCurrentlyDeductible": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets accrued compensation not currently deductible.", "label": "Deferred Tax Assets Accrued Compensation Not Currently Deductible", "terseLabel": "Accrued compensation not currently deductible" } } }, "localname": "DeferredTaxAssetsAccruedCompensationNotCurrentlyDeductible", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "atnf_DeferredTaxAssetsAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets amortization.", "label": "Deferred Tax Assets Amortization", "terseLabel": "Amortization" } } }, "localname": "DeferredTaxAssetsAmortization", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "atnf_DeferredTaxAssetsBeginning": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Beginning", "terseLabel": "Beginning of period" } } }, "localname": "DeferredTaxAssetsBeginning", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofvaluationdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "atnf_DeferredTaxAssetsBeginningEnding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Beginning Ending", "terseLabel": "End of period" } } }, "localname": "DeferredTaxAssetsBeginningEnding", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofvaluationdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "atnf_DerivativeLiabilitie": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Derivative Liabilitie", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "DerivativeLiabilitie", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "atnf_DerivativeLiabilitiesConverted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Derivative Liabilities Converted", "terseLabel": "Derivative Liabilities Converted" } } }, "localname": "DerivativeLiabilitiesConverted", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "atnf_DerivativeLiabilitiesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities (Details) [Line Items]" } } }, "localname": "DerivativeLiabilitiesDetailsLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "atnf_DerivativeLiabilitiesDetailsScheduleofoutstandingandexercisablewarrantsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities (Details) - Schedule of outstanding and exercisable warrants [Line Items]" } } }, "localname": "DerivativeLiabilitiesDetailsScheduleofoutstandingandexercisablewarrantsLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "stringItemType" }, "atnf_DerivativeLiabilitiesDetailsScheduleofoutstandingandexercisablewarrantsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities (Details) - Schedule of outstanding and exercisable warrants [Table]" } } }, "localname": "DerivativeLiabilitiesDetailsScheduleofoutstandingandexercisablewarrantsTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "stringItemType" }, "atnf_DerivativeLiabilitiesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities (Details) [Table]" } } }, "localname": "DerivativeLiabilitiesDetailsTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "atnf_DerivativeLiabilitiesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities Tables Line Items", "terseLabel": "Derivative Liabilities [Abstract]" } } }, "localname": "DerivativeLiabilitiesTablesLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "stringItemType" }, "atnf_DerivativeLiabilitiesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities (Tables) [Table]" } } }, "localname": "DerivativeLiabilitiesTablesTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "stringItemType" }, "atnf_DerivativeLiabilityBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Derivative Liability Balance", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "DerivativeLiabilityBalance", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofderivativeliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "atnf_DesignatedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Designated Shares", "terseLabel": "Designated shares (in Shares)" } } }, "localname": "DesignatedShares", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "atnf_DifferenceBetweenBookAndTaxBasisRelatedToAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Difference Between Book And Tax Basis Related To Abstract", "terseLabel": "Difference between book and tax basis related to:" } } }, "localname": "DifferenceBetweenBookAndTaxBasisRelatedToAbstract", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "atnf_DiscountedNoteConversionPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of discounted note conversion price.", "label": "Discounted Note Conversion Price", "terseLabel": "Discounted note conversion price" } } }, "localname": "DiscountedNoteConversionPrice", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "percentItemType" }, "atnf_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_DomesticAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Domestic Abstract", "terseLabel": "Domestic:" } } }, "localname": "DomesticAbstract", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofincometaxbenefitsprovisionTable" ], "xbrltype": "stringItemType" }, "atnf_DomesticFederalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DomesticFederalMember", "label": "Domestic Federal Member", "terseLabel": "Domestic Federal [Member]" } } }, "localname": "DomesticFederalMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "atnf_DominionCapitalLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dominion Capital LLCMember", "terseLabel": "Dominion Capital LLC [Member]" } } }, "localname": "DominionCapitalLLCMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "atnf_DominionConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dominion Convertible Promissory Note Member", "terseLabel": "Dominion Convertible Promissory Note [Member]" } } }, "localname": "DominionConvertiblePromissoryNoteMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable", "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable" ], "xbrltype": "domainItemType" }, "atnf_DominionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dominion Member", "terseLabel": "Dominion [Member]" } } }, "localname": "DominionMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable" ], "xbrltype": "domainItemType" }, "atnf_EarlyBirdFindersFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EarlyBirdFinder'sFeeMember", "label": "Early Bird Finders Fee Member", "terseLabel": "EarlyBird Finder\u2019s Fee [Member]" } } }, "localname": "EarlyBirdFindersFeeMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_EffectOfForeignExchangeRates": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effect of Foreign Exchange Rates.", "label": "Effect Of Foreign Exchange Rates", "terseLabel": "Effect of Foreign Exchange Rates" } } }, "localname": "EffectOfForeignExchangeRates", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "monetaryItemType" }, "atnf_EightEightPointSixZeroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Eight Eight Point Six Zero Member", "terseLabel": "88.60 [Member]" } } }, "localname": "EightEightPointSixZeroMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablestockoptionsTable" ], "xbrltype": "domainItemType" }, "atnf_EstimatingBlackScholesValuationMethodTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of estimated black scholes valuation method.", "label": "Estimating Black Scholes Valuation Method Table Text Block", "terseLabel": "Schedule of estimated using the black scholes valuation method assumptions" } } }, "localname": "EstimatingBlackScholesValuationMethodTableTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "atnf_EvotecMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EvotecMember", "label": "Evotec Member", "terseLabel": "Evotec [Member]" } } }, "localname": "EvotecMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_ExchangeAnAggregatePrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of exchange an aggregate principal amount.", "label": "Exchange An Aggregate Principal Amount", "terseLabel": "Exchange an aggregate principal amount" } } }, "localname": "ExchangeAnAggregatePrincipalAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_ExchangeOfCommonStockEquivalentsForCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Exchange Of Common Stock Equivalents For Common Stock", "terseLabel": "Exchange of common stock equivalents for common stock" } } }, "localname": "ExchangeOfCommonStockEquivalentsForCommonStock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_ExercisePrice10000Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price10000 Member", "terseLabel": "100.00 [Member]" } } }, "localname": "ExercisePrice10000Member", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "domainItemType" }, "atnf_ExercisePrice10560Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price10560 Member", "terseLabel": "105.60 [Member]" } } }, "localname": "ExercisePrice10560Member", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "domainItemType" }, "atnf_ExercisePrice14140Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price14140 Member", "terseLabel": "141.40 [Member]" } } }, "localname": "ExercisePrice14140Member", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "domainItemType" }, "atnf_ExercisePrice15000Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price15000 Member", "terseLabel": "150.00 [Member]" } } }, "localname": "ExercisePrice15000Member", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "domainItemType" }, "atnf_ExercisePrice2120Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price2120 Member", "terseLabel": "21.20 [Member]" } } }, "localname": "ExercisePrice2120Member", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "domainItemType" }, "atnf_ExercisePrice23000Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price23000 Member", "terseLabel": "230.00 [Member]" } } }, "localname": "ExercisePrice23000Member", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "domainItemType" }, "atnf_ExercisePrice350Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price350 Member", "terseLabel": "3.50 [Member]" } } }, "localname": "ExercisePrice350Member", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "domainItemType" }, "atnf_ExtinguishmentOfDerivativeLiabilitiesInConnectionWithConversionOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of extinguishment of derivative liabilities in connection with conversion of debt.", "label": "Extinguishment Of Derivative Liabilities In Connection With Conversion Of Debt", "terseLabel": "Extinguishment of derivative liabilities in connection with conversion of debt" } } }, "localname": "ExtinguishmentOfDerivativeLiabilitiesInConnectionWithConversionOfDebt", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "atnf_ExtinguishmentOfDerivativeLiabilitiesInConnectionWithTheAlphaSettlement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Extinguishment of derivative liabilities inconnection with the alpha settlement.", "label": "Extinguishment Of Derivative Liabilities In Connection With The Alpha Settlement", "terseLabel": "Extinguishment of derivative liabilities in connection with the Alpha settlement" } } }, "localname": "ExtinguishmentOfDerivativeLiabilitiesInConnectionWithTheAlphaSettlement", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "atnf_FairValueAssumptionExpectedDividendRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).", "label": "Fair Value Assumption Expected Dividend Rate", "terseLabel": "Expected dividends" } } }, "localname": "FairValueAssumptionExpectedDividendRate", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionpricingmodelsTable" ], "xbrltype": "percentItemType" }, "atnf_FairValueAssumptionsExpectedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Fair Value Assumptions Expected Term", "terseLabel": "Expected term in years" } } }, "localname": "FairValueAssumptionsExpectedTerm", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionpricingmodelsTable" ], "xbrltype": "durationItemType" }, "atnf_FairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk-free interest rate assumption used in valuing an instrument.", "label": "Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "FairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionpricingmodelsTable" ], "xbrltype": "percentItemType" }, "atnf_FairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average expected volatility of stock price.", "label": "Fair Value Assumptions Weighted Average Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "FairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionpricingmodelsTable" ], "xbrltype": "percentItemType" }, "atnf_FairValueOfPIPEWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of fair value of warrants classified as PIPE warrants.", "label": "Fair Value Of PIPEWarrants", "terseLabel": "Fair value of PIPE warrants" } } }, "localname": "FairValueOfPIPEWarrants", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_FairValueOfTheAlphaWarrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the alpha warrant.", "label": "Fair Value Of The Alpha Warrant", "terseLabel": "Fair value of the alpha warrant" } } }, "localname": "FairValueOfTheAlphaWarrant", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_FairValueOfTheCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the common stock.", "label": "Fair Value Of The Common Stock", "terseLabel": "Fair value of the common stock" } } }, "localname": "FairValueOfTheCommonStock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_FairValueOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of fair value of warrants.", "label": "Fair Value Of Warrants", "terseLabel": "Fair value of warrants" } } }, "localname": "FairValueOfWarrants", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_FifthOxfordAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fifth Oxford Agreement Member", "terseLabel": "Fifth Oxford Agreement [Member]" } } }, "localname": "FifthOxfordAgreementMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_FirstAssurance2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "First Assurance2020 Member", "terseLabel": "First Assurance - 2020 [Member]" } } }, "localname": "FirstAssurance2020Member", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "domainItemType" }, "atnf_FirstAssurance2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "First Assurance2021 Member", "terseLabel": "First Assurance \u2013 2021 [Member]" } } }, "localname": "FirstAssurance2021Member", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "domainItemType" }, "atnf_FirstAssurance2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "First Assurance2022 Member", "terseLabel": "First Assurance \u2013 2022 [Member]" } } }, "localname": "FirstAssurance2022Member", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "domainItemType" }, "atnf_FirstAssuranceFundingToFinance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of first assurance funding to finance.", "label": "First Assurance Funding To Finance", "terseLabel": "First assurance funding to finance" } } }, "localname": "FirstAssuranceFundingToFinance", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_FormerOfficersDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Former Officers Directors Member", "terseLabel": "Former Officers, Directors [Member]" } } }, "localname": "FormerOfficersDirectorsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "atnf_FourNinePointEightZeroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Four Nine Point Eight Zero Member", "terseLabel": "49.80 [Member]" } } }, "localname": "FourNinePointEightZeroMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablestockoptionsTable" ], "xbrltype": "domainItemType" }, "atnf_GeneralAndAdministrativeRelatedParties": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of general and administrative - related parties.", "label": "General And Administrative Related Parties", "terseLabel": "General and administrative - related parties" } } }, "localname": "GeneralAndAdministrativeRelatedParties", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "atnf_GoingConcernAndManagementsPlansAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern And Managements Plans Abstract" } } }, "localname": "GoingConcernAndManagementsPlansAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_GoingConcernAndManagementsPlansTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern And Managements Plans Text Block", "terseLabel": "GOING CONCERN AND MANAGEMENT'S PLANS" } } }, "localname": "GoingConcernAndManagementsPlansTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/GoingConcernandManagementsPlans" ], "xbrltype": "textBlockItemType" }, "atnf_GoingConcernandManagementsPlansLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern and Management\u2019s Plans [Abstract]" } } }, "localname": "GoingConcernandManagementsPlansLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/GoingConcernandManagementsPlans" ], "xbrltype": "stringItemType" }, "atnf_GoingConcernandManagementsPlansTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern and Management's Plans [Table]" } } }, "localname": "GoingConcernandManagementsPlansTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/GoingConcernandManagementsPlans" ], "xbrltype": "stringItemType" }, "atnf_GrantRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of grant rate.", "label": "Grant Rate Percentage", "terseLabel": "Grant rate percentage" } } }, "localname": "GrantRatePercentage", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "atnf_GrantedOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Granted Options", "terseLabel": "Granted options" } } }, "localname": "GrantedOptions", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "atnf_GrossProceedsFromSaleOfStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of gross proceeds from the sale of stock.", "label": "Gross Proceeds From Sale Of Stock", "terseLabel": "Aggregate gross proceeds" } } }, "localname": "GrossProceedsFromSaleOfStock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_ImpactOfExtinguishment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impact of Extinguishment.", "label": "Impact Of Extinguishment", "terseLabel": "Impact of Extinguishment" } } }, "localname": "ImpactOfExtinguishment", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable" ], "xbrltype": "monetaryItemType" }, "atnf_ImpairmentOfIntangibleAssetFinitelived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment Of Intangible Asset Finitelived", "terseLabel": "Impaired assets" } } }, "localname": "ImpairmentOfIntangibleAssetFinitelived", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "atnf_IncomeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Income Tax", "terseLabel": "Total" } } }, "localname": "IncomeTax", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofincometaxdomesticandinternationalcomponentsTable" ], "xbrltype": "monetaryItemType" }, "atnf_IncomeTaxesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Line Items]" } } }, "localname": "IncomeTaxesDetailsLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "atnf_IncomeTaxesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Table]" } } }, "localname": "IncomeTaxesDetailsTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "atnf_IncomeTaxesTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes Tables Line Items", "terseLabel": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxesTablesLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "atnf_IncomeTaxesTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Tables) [Table]" } } }, "localname": "IncomeTaxesTablesTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "atnf_IncreaseOrDecreaseInAccountsPayableRelatedParties": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase Or Decrease In Accounts Payable Related Parties", "terseLabel": "Accounts payable \u2013 related parties" } } }, "localname": "IncreaseOrDecreaseInAccountsPayableRelatedParties", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_IncurredOfDamages": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of compensatory damages refer to the money awarded in a court case to a plaintiff to compensate for damages or other incurred losses, such as injuries.", "label": "Incurred Of Damages", "terseLabel": "Incurred damages" } } }, "localname": "IncurredOfDamages", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_InitialSalary": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial salary", "label": "Initial Salary", "terseLabel": "Initial salary" } } }, "localname": "InitialSalary", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_InitialSalarySubjectToIncreaseCompletion": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial salary subject to increase completion", "label": "Initial Salary Subject To Increase Completion", "terseLabel": "Initial salary subject to increase completion" } } }, "localname": "InitialSalarySubjectToIncreaseCompletion", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_InitialTermOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial term of agreement.", "label": "Initial Term Of Agreement", "terseLabel": "Initial term of agreement" } } }, "localname": "InitialTermOfAgreement", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "atnf_InprocessResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "In-process research and development.", "label": "Inprocess Research And Development", "terseLabel": "In-process research and development" } } }, "localname": "InprocessResearchAndDevelopment", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "atnf_InsuranceValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of insurance value.", "label": "Insurance Value", "terseLabel": "Total D&O insurance amount" } } }, "localname": "InsuranceValue", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_IntangibleAssetsAndInProcessResearchAndDevelopmentPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Assets and In-Process Research and Development.", "label": "Intangible Assets And In Process Research And Development Policy Text Block", "terseLabel": "Intangible Assets and In-Process Research and Development (\u201cIP R&D\u201d)" } } }, "localname": "IntangibleAssetsAndInProcessResearchAndDevelopmentPolicyTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "atnf_IntangibleAssetsandImpairmentofLongLivedAssetsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets and Impairment of Long-Lived Assets (Details) [Line Items]" } } }, "localname": "IntangibleAssetsandImpairmentofLongLivedAssetsDetailsLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails" ], "xbrltype": "stringItemType" }, "atnf_IntangibleAssetsandImpairmentofLongLivedAssetsDetailsScheduleoffutureamortizationrelatedtointangibleassetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Future Amortization Related to Intangible Assets [Abstract]" } } }, "localname": "IntangibleAssetsandImpairmentofLongLivedAssetsDetailsScheduleoffutureamortizationrelatedtointangibleassetsLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable" ], "xbrltype": "stringItemType" }, "atnf_IntangibleAssetsandImpairmentofLongLivedAssetsDetailsScheduleoffutureamortizationrelatedtointangibleassetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets and Impairment of Long-Lived Assets (Details) - Schedule of future amortization related to intangible assets [Table]" } } }, "localname": "IntangibleAssetsandImpairmentofLongLivedAssetsDetailsScheduleoffutureamortizationrelatedtointangibleassetsTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable" ], "xbrltype": "stringItemType" }, "atnf_IntangibleAssetsandImpairmentofLongLivedAssetsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets and Impairment of Long-Lived Assets (Details) [Table]" } } }, "localname": "IntangibleAssetsandImpairmentofLongLivedAssetsDetailsTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails" ], "xbrltype": "stringItemType" }, "atnf_InterestExpenseOnConvertibleDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on convertible debt.", "label": "Interest Expense On Convertible Debt", "terseLabel": "Interest expense on convertible debt" } } }, "localname": "InterestExpenseOnConvertibleDebt", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_InterestExpenseOnLoansPayableDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest expense on loans payable, description.", "label": "Interest Expense On Loans Payable Description", "terseLabel": "Interest expense on loans payable, description." } } }, "localname": "InterestExpenseOnLoansPayableDescription", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "stringItemType" }, "atnf_InterestExpenseOnRelatedPartyLoans": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Interest expense on related party loans.", "label": "Interest Expense On Related Party Loans", "terseLabel": "Interest expense on related party loans" } } }, "localname": "InterestExpenseOnRelatedPartyLoans", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_InterestExpenseRelatedParties": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest expense - related parties.", "label": "Interest Expense Related Parties", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseRelatedParties", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "atnf_InterestOnConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest On Convertible Notes Member", "terseLabel": "Interest on Convertible Notes [Member]" } } }, "localname": "InterestOnConvertibleNotesMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "atnf_IntrinsicValueExercisableEnding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic Value, Exercisable ending", "label": "Intrinsic Value Exercisable Ending", "terseLabel": "Intrinsic Value, Exercisable ending" } } }, "localname": "IntrinsicValueExercisableEnding", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "monetaryItemType" }, "atnf_Investors": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investors", "terseLabel": "Investors" } } }, "localname": "Investors", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "percentItemType" }, "atnf_IssuanceOfPrefundedWarrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuance of prefunded warrants.", "label": "Issuance Of Prefunded Warrant", "terseLabel": "Issuance of December 2022 pre-funded warrants" } } }, "localname": "IssuanceOfPrefundedWarrant", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "atnf_IssuanceOfPrefundedWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of shares issuance of pre funded warrants.", "label": "Issuance Of Prefunded Warrants", "terseLabel": "Issuance of July 2022 pre-funded warrants" } } }, "localname": "IssuanceOfPrefundedWarrants", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "atnf_July2022CommonWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "July2022 Common Warrants Member", "label": "July2022 Common Warrants Member", "terseLabel": "July2022 Common Warrants [Member]" } } }, "localname": "July2022CommonWarrantsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "atnf_JulyTwentyTwoPreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "July Twenty Two Pre Funded Warrants Member.", "label": "July Twenty Two Pre Funded Warrants Member", "terseLabel": "July Twenty Two Pre Funded Warrants [Member]" } } }, "localname": "JulyTwentyTwoPreFundedWarrantsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "atnf_KBLConvertibleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "KBLConvertible Member", "terseLabel": "KBL Convertible [Member]" } } }, "localname": "KBLConvertibleMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "atnf_KBLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "KBLMember", "terseLabel": "KBL [Member]" } } }, "localname": "KBLMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_KatexcoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KatexcoMember", "label": "Katexco Member", "terseLabel": "Katexco [Member]" } } }, "localname": "KatexcoMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_KblCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kbl Common Stock", "label": "Kbl Common Stock", "terseLabel": "KBL commons stock (in Shares)" } } }, "localname": "KblCommonStock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "sharesItemType" }, "atnf_KennedyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KennedyMember", "label": "Kennedy Member", "terseLabel": "Kennedy [Member]" } } }, "localname": "KennedyMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_KingsbrookConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Kingsbrook Convertible Promissory Note Member", "terseLabel": "Kingsbrook Convertible Promissory Note [Member]" } } }, "localname": "KingsbrookConvertiblePromissoryNoteMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable", "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable" ], "xbrltype": "domainItemType" }, "atnf_KingsbrookMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Kingsbrook Member", "terseLabel": "Kingsbrook [Member]" } } }, "localname": "KingsbrookMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable", "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "domainItemType" }, "atnf_LPConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LPConvertible Note Member", "terseLabel": "180 LP Convertible Note [Member]" } } }, "localname": "LPConvertibleNoteMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "atnf_LPConvertibleNoteThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LPConvertible Note Three Member", "terseLabel": "180 LP Convertible Note\tthree [Member]" } } }, "localname": "LPConvertibleNoteThreeMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "atnf_LPConvertibleNoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LPConvertible Note Two Member", "terseLabel": "180 LP Convertible Note\ttwo [Member]" } } }, "localname": "LPConvertibleNoteTwoMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "atnf_LPGoodwillMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LPGoodwill Member", "terseLabel": "180 LP Goodwill [Member]" } } }, "localname": "LPGoodwillMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable" ], "xbrltype": "domainItemType" }, "atnf_LPIPRDAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LPIPRDAssets Member", "terseLabel": "180 LP IP R&D Assets" } } }, "localname": "LPIPRDAssetsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable" ], "xbrltype": "domainItemType" }, "atnf_LPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LPMember", "label": "LPMember", "terseLabel": "LP [Member]" } } }, "localname": "LPMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_LicenseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License fee", "label": "License Fee", "terseLabel": "Initial License fee" } } }, "localname": "LicenseFee", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_LitigationAccrual": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable": { "order": 3.0, "parentTag": "atnf_AccruedLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Litigation Accrual", "terseLabel": "Litigation accrual" } } }, "localname": "LitigationAccrual", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable" ], "xbrltype": "monetaryItemType" }, "atnf_LitigationReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Litigation receivable.", "label": "Litigation Receivable", "terseLabel": "Litigation receivable (Note 11)" } } }, "localname": "LitigationReceivable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "monetaryItemType" }, "atnf_LoanForgivenessAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loan forgiveness amount.", "label": "Loan Forgiveness Amount", "terseLabel": "Loan forgiveness amount" } } }, "localname": "LoanForgivenessAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_LoanPayableIssuedEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Eight Member", "terseLabel": "Loan payable issued March 31, 2020 [Member]" } } }, "localname": "LoanPayableIssuedEightMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Eighteen Member", "terseLabel": "Loan payable issued October 14, 2020 [Member]" } } }, "localname": "LoanPayableIssuedEighteenMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedElevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Eleven Member", "terseLabel": "Loan payable issued June 8, 2020 [Member]" } } }, "localname": "LoanPayableIssuedElevenMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedFifteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Fifteen Member", "terseLabel": "Loan payable issued July 15, 2020 [Member]" } } }, "localname": "LoanPayableIssuedFifteenMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Five Member", "terseLabel": "Loan payable issued December 31, 2019 [Member]", "verboseLabel": "Loan payable issued July 15, 2020 [Member]" } } }, "localname": "LoanPayableIssuedFiveMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable", "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Four Member", "terseLabel": "Loan payable issued October 29, 2019 [Member]", "verboseLabel": "Loan payable issued June 17, 2020 [Member]" } } }, "localname": "LoanPayableIssuedFourMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable", "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Member", "terseLabel": "Loan payable issued September 18, 2019 [Member]" } } }, "localname": "LoanPayableIssuedMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Nine Member", "terseLabel": "Loan payable issued March 31, 2020 [Member]" } } }, "localname": "LoanPayableIssuedNineMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Nineteen Member", "terseLabel": "Current portion of PPP Loans [Member]" } } }, "localname": "LoanPayableIssuedNineteenMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Seven Member", "terseLabel": "Loan payable issued February 5, 2020 [Member]", "verboseLabel": "Loan payable issued October 14, 2020 [Member]" } } }, "localname": "LoanPayableIssuedSevenMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable", "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedSeventeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Seventeen Member", "terseLabel": "Loan payable issued October 13, 2020 [Member]" } } }, "localname": "LoanPayableIssuedSeventeenMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Six Member", "terseLabel": "Loan payable issued February 5, 2020 [Member]", "verboseLabel": "Loan payable issued October 8, 2020 [Member]" } } }, "localname": "LoanPayableIssuedSixMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable", "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedSixteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Sixteen Member", "terseLabel": "Loan payable issued October 8, 2020 [Member]" } } }, "localname": "LoanPayableIssuedSixteenMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedTenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Ten Member", "terseLabel": "Loan payable issued June 8, 2020 [Member]" } } }, "localname": "LoanPayableIssuedTenMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedThirteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Thirteen Member", "terseLabel": "Loan payable issued July 15, 2020 [Member]" } } }, "localname": "LoanPayableIssuedThirteenMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Three Member", "terseLabel": "Loan payable issued October 8, 2019 [Member]", "verboseLabel": "Loan payable issued March 31, 2020 [Member]" } } }, "localname": "LoanPayableIssuedThreeMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable", "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedTwelveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Twelve Member", "terseLabel": "Loan payable issued June 17, 2020 [Member]" } } }, "localname": "LoanPayableIssuedTwelveMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Twenty Member", "terseLabel": "Current portion of Bounce Back Loans [Member]" } } }, "localname": "LoanPayableIssuedTwentyMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayableIssuedTwentyoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable Issued Twentyone Member", "terseLabel": "First Assurance Funding payable issued December 10, 2021 [Member]" } } }, "localname": "LoanPayableIssuedTwentyoneMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "domainItemType" }, "atnf_LoanPayablePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Payable Percentage.", "label": "Loan Payable Percentage", "terseLabel": "Loans payable percentage" } } }, "localname": "LoanPayablePercentage", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "percentItemType" }, "atnf_LoanProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loan proceeds.", "label": "Loan Proceeds", "terseLabel": "Loan proceeds" } } }, "localname": "LoanProceeds", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_LoansPayableCurrentPortions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable Current Portions", "terseLabel": "Loans payable current portion" } } }, "localname": "LoansPayableCurrentPortions", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "monetaryItemType" }, "atnf_LoansPayableDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans Payable (Details) [Line Items]" } } }, "localname": "LoansPayableDetailsLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "stringItemType" }, "atnf_LoansPayableDetailsScheduleofloanspayableactivityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans Payable (Details) - Schedule of loans payable activity [Line Items]" } } }, "localname": "LoansPayableDetailsScheduleofloanspayableactivityLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "stringItemType" }, "atnf_LoansPayableDetailsScheduleofloanspayableactivityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans Payable (Details) - Schedule of loans payable activity [Table]" } } }, "localname": "LoansPayableDetailsScheduleofloanspayableactivityTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "stringItemType" }, "atnf_LoansPayableDetailsScheduleofnoncurrentloanspayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans Payable (Details) - Schedule of non-current loans payable [Line Items]" } } }, "localname": "LoansPayableDetailsScheduleofnoncurrentloanspayableLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofnoncurrentloanspayableTable" ], "xbrltype": "stringItemType" }, "atnf_LoansPayableDetailsScheduleofnoncurrentloanspayableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans Payable (Details) - Schedule of non-current loans payable [Table]" } } }, "localname": "LoansPayableDetailsScheduleofnoncurrentloanspayableTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofnoncurrentloanspayableTable" ], "xbrltype": "stringItemType" }, "atnf_LoansPayableDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans Payable (Details) [Table]" } } }, "localname": "LoansPayableDetailsTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "stringItemType" }, "atnf_LoansPayableIssuedOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans Payable Issued One Member", "terseLabel": "Loan payable issued September 18, 2019 [Member]", "verboseLabel": "Loan payable issued October 8, 2019 [Member]" } } }, "localname": "LoansPayableIssuedOneMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable", "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "domainItemType" }, "atnf_LoansPayableIssuedTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans Payable Issued Two Member", "terseLabel": "Loan payable issued September 18, 2019 [Member]", "verboseLabel": "Loan payable issued February 5, 2020 [Member]" } } }, "localname": "LoansPayableIssuedTwoMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable", "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "domainItemType" }, "atnf_LoansPayableNonCurrentPortion": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loans payable non current portion.", "label": "Loans Payable Non Current Portion", "terseLabel": "Loans payable - noncurrent portion" } } }, "localname": "LoansPayableNonCurrentPortion", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "atnf_LoansPayableNonCurrentPortions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable Non Current Portions", "terseLabel": "Loans payable Non current portion" } } }, "localname": "LoansPayableNonCurrentPortions", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofnoncurrentloanspayableTable" ], "xbrltype": "monetaryItemType" }, "atnf_LoansPayableRelatedParties": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loans payable - related parties.", "label": "Loans Payable Related Parties", "terseLabel": "Loans payable - related parties" } } }, "localname": "LoansPayableRelatedParties", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "atnf_LoansPayableRelatedPartiesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loans payable - related parties.", "label": "Loans Payable Related Parties Amount", "terseLabel": "Loans payable - related parties" } } }, "localname": "LoansPayableRelatedPartiesAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_LoansPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans Payable Text Block", "terseLabel": "LOANS PAYABLE" } } }, "localname": "LoansPayableTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayable" ], "xbrltype": "textBlockItemType" }, "atnf_LossOnExtinguishmentOfConvertibleNotePayable": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Loss On Extinguishment Of Convertible Note Payable", "terseLabel": "Loss on extinguishment of convertible note payable" } } }, "localname": "LossOnExtinguishmentOfConvertibleNotePayable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_MaintenanceFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maintenance fee", "label": "Maintenance Fee", "terseLabel": "Annual maintenance fee" } } }, "localname": "MaintenanceFee", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_MarketValueOfTradedStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The market value represents the value of a company according to the stock market. It is the price an asset would get in the marketplace.", "label": "Market Value Of Traded Stock", "terseLabel": "Market value traded stock" } } }, "localname": "MarketValueOfTradedStock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "atnf_MaximumLoanAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum loan amount.", "label": "Maximum Loan Amount", "terseLabel": "Maximum loan amount (in Pounds)" } } }, "localname": "MaximumLoanAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_MaximumPenaltiesForEventOfDefaults": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum penalties for event of defaults.", "label": "Maximum Penalties For Event Of Defaults", "terseLabel": "Maximum purchase aggregate amount" } } }, "localname": "MaximumPenaltiesForEventOfDefaults", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_MonthlyInstallmentLoans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of monthly installment loans.", "label": "Monthly Installment Loans", "terseLabel": "Monthly installment loans" } } }, "localname": "MonthlyInstallmentLoans", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_NegotitationProvide": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "NegotitationProvide", "label": "Negotitation Provide", "terseLabel": "Negotiation provide" } } }, "localname": "NegotitationProvide", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_NetBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net Balance", "terseLabel": "Net, Balance at Ending" } } }, "localname": "NetBalance", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "atnf_NetImpactOfConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net Impact Of Conversion", "terseLabel": "Net, Impact of conversion" } } }, "localname": "NetImpactOfConversion", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "atnf_NetImpactOfExtinguishment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net Impact Of Extinguishment", "terseLabel": "Net, Impact of extinguishment" } } }, "localname": "NetImpactOfExtinguishment", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "atnf_NetValueOfPreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net value of preferred stock.", "label": "Net Value Of Preferred Stock", "terseLabel": "Net of preferred stock" } } }, "localname": "NetValueOfPreferredStock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_NumberOfOptionsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Options, Expired.", "label": "Number Of Options Expired", "terseLabel": "Number of Options, Expired" } } }, "localname": "NumberOfOptionsExpired", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "sharesItemType" }, "atnf_NumberOfWarrantsCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number Of Warrants Cancelled", "terseLabel": "Number of Warrants, Cancelled" } } }, "localname": "NumberOfWarrantsCancelled", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "sharesItemType" }, "atnf_NumberOfWarrantsExercisableBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares warrants, exercisable balance.", "label": "Number Of Warrants Exercisable Balance", "terseLabel": "Number of Warrants, Exercisable" } } }, "localname": "NumberOfWarrantsExercisableBalance", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "sharesItemType" }, "atnf_NumberOfWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number Of Warrants Exercised", "terseLabel": "Number of Warrants, Exercised" } } }, "localname": "NumberOfWarrantsExercised", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "sharesItemType" }, "atnf_NumberOfWarrantsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants, expired.", "label": "Number Of Warrants Expired", "terseLabel": "Number of Warrants, Expired" } } }, "localname": "NumberOfWarrantsExpired", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "sharesItemType" }, "atnf_NumberOfWarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants, issued.", "label": "Number Of Warrants Issued", "terseLabel": "Number of Warrants, Issued" } } }, "localname": "NumberOfWarrantsIssued", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "sharesItemType" }, "atnf_NumberOfWarrantsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number Of Warrants Outstanding", "periodEndLabel": "Number of Warrants Outstanding, Ending balance", "periodStartLabel": "Number of Warrants Outstanding, Beginning balance" } } }, "localname": "NumberOfWarrantsOutstanding", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "sharesItemType" }, "atnf_OfferingCostsAllocatedToWarrantLiabilities": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 9.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Offering costs allocated to warrant liabilities.", "label": "Offering Costs Allocated To Warrant Liabilities", "terseLabel": "Offering costs allocated to warrant liabilities" } } }, "localname": "OfferingCostsAllocatedToWarrantLiabilities", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow", "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "atnf_OfferingCostsInConnectionWith2021SaleOfStockAndWarrants": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Offering costs in connection with sale of common stock and warrants.", "label": "Offering Costs In Connection With2021 Sale Of Stock And Warrants", "terseLabel": "Offering costs in connection with 2021 sale of stock and warrants" } } }, "localname": "OfferingCostsInConnectionWith2021SaleOfStockAndWarrants", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_OfferingCostsInConnectionWithJuly2022SaleOfCommonStockAndCommonWarrants": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Offering costs in connection with sale of common stock and warrants.", "label": "Offering Costs In Connection With July2022 Sale Of Common Stock And Common Warrants", "terseLabel": "Offering costs in connection with July 2022 sale of common stock and common stock warrants" } } }, "localname": "OfferingCostsInConnectionWithJuly2022SaleOfCommonStockAndCommonWarrants", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_OfferingCostsInConnectionWithSaleOfCommonStockAndWarrants": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Offering Costs In Connection With Sale Of Common Stock And Warrants", "terseLabel": "Offering costs in connection with December 2022 sale of common stock and common stock warrants" } } }, "localname": "OfferingCostsInConnectionWithSaleOfCommonStockAndWarrants", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_OfficersAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Officers And Directors Member", "terseLabel": "Officers and Directors [Member]" } } }, "localname": "OfficersAndDirectorsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "atnf_OneEightZeroLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "One Eight Zero LPMember", "terseLabel": "180 LP [Member]" } } }, "localname": "OneEightZeroLPMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails" ], "xbrltype": "domainItemType" }, "atnf_OneFiveOnePointTwoZeroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "One Five One Point Two Zero Member", "terseLabel": "151.20 [Member]" } } }, "localname": "OneFiveOnePointTwoZeroMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablestockoptionsTable" ], "xbrltype": "domainItemType" }, "atnf_OneyearAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "OneyearAgreement", "label": "Oneyear Agreement", "terseLabel": "One year agreement" } } }, "localname": "OneyearAgreement", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_OptionPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Option payment", "label": "Option Payment", "terseLabel": "Option payment" } } }, "localname": "OptionPayment", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_OriginalIssuanceDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Original Issuance Discount", "terseLabel": "Stated value" } } }, "localname": "OriginalIssuanceDiscount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_OtherAccruedLiabilities": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable": { "order": 7.0, "parentTag": "atnf_AccruedLiabilities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities", "negatedLabel": "Other" } } }, "localname": "OtherAccruedLiabilities", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable" ], "xbrltype": "monetaryItemType" }, "atnf_OtherLoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Loans Payable Member", "terseLabel": "Other loans payable [Member]" } } }, "localname": "OtherLoansPayableMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "domainItemType" }, "atnf_OtherWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Warrants Member", "terseLabel": "Other Warrants [Member]" } } }, "localname": "OtherWarrantsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofderivativeliabilitiesTable", "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "atnf_OxfordMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OxfordMember", "label": "Oxford Member", "terseLabel": "Oxford [Member]" } } }, "localname": "OxfordMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_OxfordUniversityAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oxford university agreements.", "label": "Oxford University Agreements Member", "terseLabel": "Oxford University Agreements [Member]" } } }, "localname": "OxfordUniversityAgreementsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_PIPEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PIPEMember", "terseLabel": "PIPE Warrants [Member]", "verboseLabel": "PIPE [Member]" } } }, "localname": "PIPEMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "atnf_PIPEWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PIPEWarrants Member", "terseLabel": "PIPE Warrants [Member]" } } }, "localname": "PIPEWarrantsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails", "http://180lifesciences.com/role/ScheduleofderivativeliabilitiesTable" ], "xbrltype": "domainItemType" }, "atnf_PPPLoanPayableIssuedNonCurrentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PPPLoan Payable Issued Non Current Two Member", "terseLabel": "PPP loan payable issued May 5, 2020 [Member]" } } }, "localname": "PPPLoanPayableIssuedNonCurrentTwoMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofnoncurrentloanspayableTable" ], "xbrltype": "domainItemType" }, "atnf_PPPLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PPPLoans Member", "terseLabel": "PPP Loans [Member]" } } }, "localname": "PPPLoansMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "domainItemType" }, "atnf_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Paycheck Protection Program Member", "terseLabel": "Paycheck Protection Program [Member]" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "domainItemType" }, "atnf_PaymentOfFirstMilestone": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment of first milestone", "label": "Payment Of First Milestone", "terseLabel": "Payment of first milestone" } } }, "localname": "PaymentOfFirstMilestone", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_PenaltiesForEventOfDefault": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of penalties for event of default.", "label": "Penalties For Event Of Default", "terseLabel": "Purchasers aggregate amount" } } }, "localname": "PenaltiesForEventOfDefault", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_PercentageOfAmendmentOrModificationInCashFlows": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of amendment or modification in cash flows.", "label": "Percentage Of Amendment Or Modification In Cash Flows", "terseLabel": "Percentage of amendment or modification in cash flows" } } }, "localname": "PercentageOfAmendmentOrModificationInCashFlows", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "percentItemType" }, "atnf_PercentageOfAutomaticAnnualSalaryIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of automatic annual salary increase", "label": "Percentage Of Automatic Annual Salary Increase", "terseLabel": "Percentage of automatic annual salary increase" } } }, "localname": "PercentageOfAutomaticAnnualSalaryIncrease", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "atnf_PercentageOfCashPayable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of cash payable.", "label": "Percentage Of Cash Payable", "terseLabel": "Percentage of cash payable" } } }, "localname": "PercentageOfCashPayable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "atnf_PercentageOfConsultantAdditionalBonus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of consultant additional bonus", "label": "Percentage Of Consultant Additional Bonus", "terseLabel": "Percentage of consultant additional bonus" } } }, "localname": "PercentageOfConsultantAdditionalBonus", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "atnf_PercentageOfConsultantBonus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of consultant bonus", "label": "Percentage Of Consultant Bonus", "terseLabel": "Percentage of consultant bonus" } } }, "localname": "PercentageOfConsultantBonus", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "atnf_PercentageOfSalariesAvailableToPaidBonus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of salaries available to paid bonus", "label": "Percentage Of Salaries Available To Paid Bonus", "terseLabel": "Salary available to paid bonus" } } }, "localname": "PercentageOfSalariesAvailableToPaidBonus", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "atnf_PercentageOfSalaryAvailableToPaidBonus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of salary available to paid bonus", "label": "Percentage Of Salary Available To Paid Bonus", "terseLabel": "Percentage of salary available to paid bonus" } } }, "localname": "PercentageOfSalaryAvailableToPaidBonus", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "atnf_PercentageOfStartDayAnniversary": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of start-day anniversary", "label": "Percentage Of Start Day Anniversary", "terseLabel": "Percentage of start day anniversary" } } }, "localname": "PercentageOfStartDayAnniversary", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "atnf_PercentageOfTargetedAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of targeted amount", "label": "Percentage Of Targeted Amount", "terseLabel": "Percentage of targeted amount" } } }, "localname": "PercentageOfTargetedAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "atnf_PermanentDifferencesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Permanent Differences Abstract", "terseLabel": "Permanent differences:" } } }, "localname": "PermanentDifferencesAbstract", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofunitedstatesfederalstatutoryrateTable" ], "xbrltype": "stringItemType" }, "atnf_PetcannaSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Petcanna Shares Member", "terseLabel": "Petcanna Shares [Member]" } } }, "localname": "PetcannaSharesMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_PharmaceuticalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PharmaceuticalMember", "label": "Pharmaceutical Member", "terseLabel": "Pharmaceutical [Member]" } } }, "localname": "PharmaceuticalMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_Pharmaceuticalagreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Pharmaceuticalagreement", "label": "Pharmaceuticalagreement", "terseLabel": "Phamaceutical agreement" } } }, "localname": "Pharmaceuticalagreement", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_PlacementAgentFeesAndOfferingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Placement agent fees and offering expenses.", "label": "Placement Agent Fees And Offering Expenses", "terseLabel": "Placement agent fees and offering expenses" } } }, "localname": "PlacementAgentFeesAndOfferingExpenses", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_PreferredStockValue1": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value1", "terseLabel": "Class C Preferred Stock; 1 share authorized, issued and outstanding at December 31, 2022 and 2021" } } }, "localname": "PreferredStockValue1", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "atnf_PreferredStockValue2": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value 2 and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value2", "terseLabel": "Class K Preferred Stock; 1 share authorized, issued and outstanding at December 31, 2022 and 2021" } } }, "localname": "PreferredStockValue2", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "atnf_PrefundedWarrantExercised": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prefunded warrant exercised", "label": "Prefunded Warrant Exercised", "terseLabel": "Warrants exercised" } } }, "localname": "PrefundedWarrantExercised", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "atnf_PrefundedWarrantShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prefunded warrant shares.", "label": "Prefunded Warrant Shares", "terseLabel": "Warrant shares (in Shares)" } } }, "localname": "PrefundedWarrantShares", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "atnf_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Prepaid Expenses [Abstract]" } } }, "localname": "PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "stringItemType" }, "atnf_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses [Table]" } } }, "localname": "PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "stringItemType" }, "atnf_PrincipalBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Principal Balance", "terseLabel": "Principal, Balance at Ending" } } }, "localname": "PrincipalBalance", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "atnf_PrincipalBalanceConverted1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Principal Balance Converted1", "terseLabel": "Principal Balance Converted" } } }, "localname": "PrincipalBalanceConverted1", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "atnf_PrincipalBalanceofConvertibleNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of principal balanceof convertible notes payable.", "label": "Principal Balanceof Convertible Notes Payable", "periodEndLabel": "Ending Principal Balance" } } }, "localname": "PrincipalBalanceofConvertibleNotesPayable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "monetaryItemType" }, "atnf_PrincipalBalancesofConvertibleNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Opening Principal Balance.", "label": "Principal Balancesof Convertible Notes Payable", "periodStartLabel": "Opening Principal Balance" } } }, "localname": "PrincipalBalancesofConvertibleNotesPayable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "monetaryItemType" }, "atnf_PrincipalImpactOfConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of principal, Impact of conversion.", "label": "Principal Impact Of Conversion", "terseLabel": "Principal, Impact of conversion" } } }, "localname": "PrincipalImpactOfConversion", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "atnf_PrincipalImpactOfExtinguishment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Principal Impact Of Extinguishment", "terseLabel": "Principal, Impact of extinguishment" } } }, "localname": "PrincipalImpactOfExtinguishment", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "atnf_PrivateSPACMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private SPACMember", "terseLabel": "Private SPAC Warrants [Member]" } } }, "localname": "PrivateSPACMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "atnf_PrivateSPACWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private SPACWarrants Member", "terseLabel": "Private SPAC Warrants [Member]" } } }, "localname": "PrivateSPACWarrantsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofderivativeliabilitiesTable" ], "xbrltype": "domainItemType" }, "atnf_PrivateWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Warrants Member", "terseLabel": "Private Warrants [Member]" } } }, "localname": "PrivateWarrantsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "atnf_ProceedsFromConvertibleNotesPayable": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds From Convertible Notes Payable", "terseLabel": "Proceeds from loans payable" } } }, "localname": "ProceedsFromConvertibleNotesPayable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_ProceedsFromExerciseOfDecember2022PrefundedWarrants": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of proceeds from exercise of pre-funded warrants.", "label": "Proceeds From Exercise Of December2022 Prefunded Warrants", "negatedLabel": "Proceeds from exercise of December 2022 pre-funded warrants" } } }, "localname": "ProceedsFromExerciseOfDecember2022PrefundedWarrants", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_ProceedsFromExerciseOfJuly2022PrefundedWarrants": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of proceeds from exercise of pre-funded warrants.", "label": "Proceeds From Exercise Of July2022 Prefunded Warrants", "negatedLabel": "Proceeds from exercise of July 2022 pre-funded warrants" } } }, "localname": "ProceedsFromExerciseOfJuly2022PrefundedWarrants", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_ProceedsFromOfficersInsurancePolicy": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of officers insurance policy.", "label": "Proceeds From Officers Insurance Policy", "terseLabel": "Directors and officers insurance policy" } } }, "localname": "ProceedsFromOfficersInsurancePolicy", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_ProceedsFromSaleOfCommonStock1": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Sale Of Common Stock1", "terseLabel": "Proceeds from sale of July 2022 common stock and common stock warrants" } } }, "localname": "ProceedsFromSaleOfCommonStock1", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_ProfessionalFeeses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Professional Feeses", "terseLabel": "Professional fees" } } }, "localname": "ProfessionalFeeses", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "monetaryItemType" }, "atnf_PublicSPACMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Public SPACMember", "terseLabel": "Public SPAC Warrants [Member]" } } }, "localname": "PublicSPACMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "atnf_PublicSPACWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Public SPACWarrants Member", "terseLabel": "Public SPAC Warrants [Member]" } } }, "localname": "PublicSPACWarrantsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofderivativeliabilitiesTable" ], "xbrltype": "domainItemType" }, "atnf_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Public Warrants Member", "terseLabel": "Public SPAC Warrants [Member]" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "atnf_RDConsultingFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of R&D consulting fees.", "label": "RDConsulting Fees", "terseLabel": "Aggregate fees" } } }, "localname": "RDConsultingFees", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_RecentlyIssuedButNotYetAdoptedAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Issued But Not Yet Adopted Accounting Pronouncements Policy Policy Text Block", "terseLabel": "Recently Issued But Not Yet Adopted Accounting Pronouncements" } } }, "localname": "RecentlyIssuedButNotYetAdoptedAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "stringItemType" }, "atnf_ReclassificationOfAccruedIssuableEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reclassification Of Accrued Issuable Equity", "terseLabel": "Reclassification of accrued issuable equity" } } }, "localname": "ReclassificationOfAccruedIssuableEquity", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_ReclassificationToEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reclassification to equity.", "label": "Reclassification To Equity", "terseLabel": "Reclassification to equity" } } }, "localname": "ReclassificationToEquity", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofaccruedissuableequityactivityTable" ], "xbrltype": "monetaryItemType" }, "atnf_ReformationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ReformationMember", "label": "Reformation Member", "terseLabel": "ReFormation [Member]" } } }, "localname": "ReformationMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_RelatedPartiesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Parties (Details) [Line Items]" } } }, "localname": "RelatedPartiesDetailsLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "atnf_RelatedPartiesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Parties (Details) [Table]" } } }, "localname": "RelatedPartiesDetailsTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "atnf_RelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Parties Member", "terseLabel": "Related Parties [Member]" } } }, "localname": "RelatedPartiesMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "atnf_RelatedPartyExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related Party Expenses", "label": "Related Party Expenses", "terseLabel": "Accrued expenses related parties" } } }, "localname": "RelatedPartyExpenses", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_RelatedPartyInterestExpenseAssociatedWithConvertibleNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of related party interest expense associated with convertible notes.", "label": "Related Party Interest Expense Associated With Convertible Notes", "terseLabel": "Related party interest expense associated with convertible notes" } } }, "localname": "RelatedPartyInterestExpenseAssociatedWithConvertibleNotes", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_RelatedPartyLoans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related Party Loans.", "label": "Related Party Loans", "terseLabel": "Loans payable, related parties" } } }, "localname": "RelatedPartyLoans", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "monetaryItemType" }, "atnf_RelatedPartyLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Loans Member", "terseLabel": "Related Party Loans [Member]" } } }, "localname": "RelatedPartyLoansMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "atnf_RepaymentOfLoansPayable": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Repayment Of Loans Payable", "negatedLabel": "Repayment of loans payable, net of adjustments (Note 9)" } } }, "localname": "RepaymentOfLoansPayable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_ResearchAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "ResearchAgreement", "label": "Research Agreement", "terseLabel": "Research agreement" } } }, "localname": "ResearchAgreement", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_ResearchAndDevelopmentExpenseTaxCreditReceivable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development expense tax credit receivable", "label": "Research And Development Expense Tax Credit Receivable", "terseLabel": "Research and development expense tax credit receivable" } } }, "localname": "ResearchAndDevelopmentExpenseTaxCreditReceivable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "monetaryItemType" }, "atnf_ResearchAndDevelopmentExpensesRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expenses - related parties.", "label": "Research And Development Expenses Related Parties", "terseLabel": "Research and development expenses - related parties" } } }, "localname": "ResearchAndDevelopmentExpensesRelatedParties", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_ResearchAndDevelopmentFees": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable": { "order": 5.0, "parentTag": "atnf_AccruedLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Research And Development Fees", "terseLabel": "Research and development fees" } } }, "localname": "ResearchAndDevelopmentFees", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable" ], "xbrltype": "monetaryItemType" }, "atnf_ResearchAndDevelopmentRelatedParties": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Research And Development Related Parties", "terseLabel": "Research and development - related parties" } } }, "localname": "ResearchAndDevelopmentRelatedParties", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "atnf_ResearchAndDevelopmentsExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expenses.", "label": "Research And Developments Expenses", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentsExpenses", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_SalaryFinancing": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Salary financing", "label": "Salary Financing", "terseLabel": "Salary financing" } } }, "localname": "SalaryFinancing", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_ScheduleOfAccruedExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses [Abstract]" } } }, "localname": "ScheduleOfAccruedExpensesAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfAccruedIssuableEquityActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Issuable Equity Activity [Abstract]" } } }, "localname": "ScheduleOfAccruedIssuableEquityActivityAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfAntiDilutiveCommonSharesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Anti Dilutive Common Shares [Abstract]" } } }, "localname": "ScheduleOfAntiDilutiveCommonSharesAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfConvertibleNotesPayableActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Convertible Notes Payable Activity Abstract" } } }, "localname": "ScheduleOfConvertibleNotesPayableActivityAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfConvertibleNotesPayableRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Convertible Notes Payable Related Parties Abstract" } } }, "localname": "ScheduleOfConvertibleNotesPayableRelatedPartiesAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfConvertiblePromissoryNotesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Convertible Promissory Notes Abstract" } } }, "localname": "ScheduleOfConvertiblePromissoryNotesAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Deferred Tax Assets And Liabilities Abstract" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Derivative Liabilities Abstract" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfEstimatedUsingTheBlackScholesValuationMethodAssumptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Estimated Using The Black Scholes Valuation Method Assumptions Abstract" } } }, "localname": "ScheduleOfEstimatedUsingTheBlackScholesValuationMethodAssumptionsAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfFairValueOfLevel3DerivativeLiabilitiesExceptThePublicSpecialPurposeAcquisitionCompaniesSpacWarrantsAsDefinedBelowWhichAreLevel1DerivativeLiabilitiesThatAreMeasuredAtFairValAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Of Level3 Derivative Liabilities Except The Public Special Purpose Acquisition Companies Spac Warrants As Defined Below Which Are Level1 Derivative Liabilities That Are Measured At Fair Val Abstract" } } }, "localname": "ScheduleOfFairValueOfLevel3DerivativeLiabilitiesExceptThePublicSpecialPurposeAcquisitionCompaniesSpacWarrantsAsDefinedBelowWhichAreLevel1DerivativeLiabilitiesThatAreMeasuredAtFairValAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfFutureAmortizationRelatedToIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Future Amortization Related To Intangible Assets Abstract" } } }, "localname": "ScheduleOfFutureAmortizationRelatedToIntangibleAssetsAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfGoodwillActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Goodwill Activity Abstract" } } }, "localname": "ScheduleOfGoodwillActivityAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfIncomeTaxBenefitsProvisionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Income Tax Benefits Provision Abstract" } } }, "localname": "ScheduleOfIncomeTaxBenefitsProvisionAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfIncomeTaxBenefitsProvisionTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income tax benefits provision.", "label": "Schedule Of Income Tax Benefits Provision Table Text Block", "terseLabel": "Schedule of income tax benefits provision" } } }, "localname": "ScheduleOfIncomeTaxBenefitsProvisionTableTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "atnf_ScheduleOfIncomeTaxDomesticAndInternationalComponentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Income Tax Domestic And International Components Abstract" } } }, "localname": "ScheduleOfIncomeTaxDomesticAndInternationalComponentsAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Intangible Assets Abstract" } } }, "localname": "ScheduleOfIntangibleAssetsAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfLoansPayableActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Loans Payable Activity Abstract" } } }, "localname": "ScheduleOfLoansPayableActivityAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfLoansPayableActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Loans Payable Activity Table Text Block", "terseLabel": "Schedule of loans payable activity" } } }, "localname": "ScheduleOfLoansPayableActivityTableTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableTables" ], "xbrltype": "textBlockItemType" }, "atnf_ScheduleOfLoansPayableOfCurrentPortionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Loans Payable Of Current Portion Abstract" } } }, "localname": "ScheduleOfLoansPayableOfCurrentPortionAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfMakeTheFollowingPaymentsToOxfordAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Make The Following Payments To Oxford Abstract" } } }, "localname": "ScheduleOfMakeTheFollowingPaymentsToOxfordAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfNonCurrentLoansPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Non Current Loans Payable Abstract" } } }, "localname": "ScheduleOfNonCurrentLoansPayableAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfNoncurrentLoansPayableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Noncurrent Loans Payable Table Text Block", "terseLabel": "Schedule of non-current loans payable" } } }, "localname": "ScheduleOfNoncurrentLoansPayableTableTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableTables" ], "xbrltype": "textBlockItemType" }, "atnf_ScheduleOfNotesPayableRelatedPartiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of notes payable related parties.", "label": "Schedule Of Notes Payable Related Parties Table Text Block", "terseLabel": "Schedule of convertible notes payable related parties" } } }, "localname": "ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "atnf_ScheduleOfOptionActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Option Activity Abstract" } } }, "localname": "ScheduleOfOptionActivityAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfOptionPricingModelsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Option Pricing Models Abstract" } } }, "localname": "ScheduleOfOptionPricingModelsAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfOutstandingAndExercisableStockOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Outstanding And Exercisable Stock Options Abstract" } } }, "localname": "ScheduleOfOutstandingAndExercisableStockOptionsAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfOutstandingAndExercisableWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Outstanding And Exercisable Warrants Abstract" } } }, "localname": "ScheduleOfOutstandingAndExercisableWarrantsAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfOutstandingAndExercisableWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Outstanding And Exercisable Warrants Table Text Block", "terseLabel": "Schedule of outstanding and exercisable warrants" } } }, "localname": "ScheduleOfOutstandingAndExercisableWarrantsTableTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "atnf_ScheduleOfPrepaidExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Prepaid Expenses Abstract" } } }, "localname": "ScheduleOfPrepaidExpensesAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfPrepaidExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Prepaid Expenses Table Text Block", "terseLabel": "Schedule of prepaid expenses" } } }, "localname": "ScheduleOfPrepaidExpensesTableTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/PrepaidExpensesandOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "atnf_ScheduleOfRelatedPartyLoansPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Related Party Loans Payable Abstract" } } }, "localname": "ScheduleOfRelatedPartyLoansPayableAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfRestrictedStockSharesGrantedAndOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Restricted Stock Shares Granted And Outstanding Abstract" } } }, "localname": "ScheduleOfRestrictedStockSharesGrantedAndOutstandingAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfSecuredConvertiblePromissoryNotesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Secured Convertible Promissory Notes Abstract" } } }, "localname": "ScheduleOfSecuredConvertiblePromissoryNotesAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfSecuredConvertiblePromissoryNotesElectedToConvertPrincipalTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Secured Convertible Promissory Notes Elected To Convert Principal Table Text Block", "terseLabel": "Schedule of secured convertible promissory notes" } } }, "localname": "ScheduleOfSecuredConvertiblePromissoryNotesElectedToConvertPrincipalTableTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "atnf_ScheduleOfSpecialVotingSharesActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Special Voting Shares Activity Abstract" } } }, "localname": "ScheduleOfSpecialVotingSharesActivityAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfUnitedStatesFederalStatutoryRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of United States Federal Statutory Rate Abstract" } } }, "localname": "ScheduleOfUnitedStatesFederalStatutoryRateAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfValuationDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Valuation Deferred Tax Assets Abstract" } } }, "localname": "ScheduleOfValuationDeferredTaxAssetsAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfWarrantActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Warrant Activity Abstract" } } }, "localname": "ScheduleOfWarrantActivityAbstract", "nsuri": "http://180lifesciences.com/20221231", "xbrltype": "stringItemType" }, "atnf_ScheduleOfWarrantActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of warrant activity table text block.", "label": "Schedule Of Warrant Activity Table Text Block", "terseLabel": "Schedule of warrant activity" } } }, "localname": "ScheduleOfWarrantActivityTableTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "atnf_SecuredConvertiblePromissoryNotePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of secured convertible promissory note.", "label": "Secured Convertible Promissory Note Percentage", "terseLabel": "Secured convertible promissory note, percentage" } } }, "localname": "SecuredConvertiblePromissoryNotePercentage", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "percentItemType" }, "atnf_SecuredConvertiblePromissoryNotepercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured convertible promissory note,percentage.", "label": "Secured Convertible Promissory Notepercentage", "terseLabel": "Secured convertible promissory note,percentage" } } }, "localname": "SecuredConvertiblePromissoryNotepercentage", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "percentItemType" }, "atnf_SeniorSecuredConvertiblePromissoryNotePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of senior secured convertible promissory note.", "label": "Senior Secured Convertible Promissory Note Percentage", "terseLabel": "Senior secured convertible promissory note, percentage" } } }, "localname": "SeniorSecuredConvertiblePromissoryNotePercentage", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "percentItemType" }, "atnf_SettlementDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "It represent settlement debt.", "label": "Settlement Debt", "terseLabel": "Settlement Debt" } } }, "localname": "SettlementDebt", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "monetaryItemType" }, "atnf_SettlementPayingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Settlement Paying Amount", "terseLabel": "Settlement paying amount" } } }, "localname": "SettlementPayingAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_SevenNinePointZeroZeroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Seven Nine Point Zero Zero Member", "terseLabel": "79.00 [Member]" } } }, "localname": "SevenNinePointZeroZeroMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablestockoptionsTable" ], "xbrltype": "domainItemType" }, "atnf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price1", "terseLabel": "Weighted Average Exercise Price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice1", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "perShareItemType" }, "atnf_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilitysRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatilitys Rate", "terseLabel": "Issued and outstanding shares" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilitysRate", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "atnf_ShareIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Share Issued", "terseLabel": "Shares issued (in Shares)" } } }, "localname": "ShareIssued", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "atnf_ShareWarrantsAggregateValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share Warrants Aggregate Value.", "label": "Share Warrants Aggregate Value", "terseLabel": "Share warrants aggregate value" } } }, "localname": "ShareWarrantsAggregateValue", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of intrinsic expired award under share-based payment arrangement. Excludes share and unit options.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Expired", "terseLabel": "Intrinsic Value, Expired" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "monetaryItemType" }, "atnf_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of forfeited award under share-based payment arrangement. Excludes share and unit options.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited", "terseLabel": "Intrinsic Value, Forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "monetaryItemType" }, "atnf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Life in Years Outstanding, Ending balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "durationItemType" }, "atnf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLifeInYearsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Life In Years Exercised", "terseLabel": "Weighted Average Remaining Life in Years, Exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLifeInYearsExercised", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "durationItemType" }, "atnf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLifeInYearsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Life In Years Issued", "terseLabel": "Weighted Average Remaining Life in Years, Issued" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLifeInYearsIssued", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "durationItemType" }, "atnf_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Option Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted Average Remaining Term (in Years), Outstanding ending" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionWeightedAverageRemainingContractualTerm2", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "durationItemType" }, "atnf_SharesCancelled": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares Cancelled", "terseLabel": "Shares issued to settle accounts payable" } } }, "localname": "SharesCancelled", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_SharesGrantDatedValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares grant dated value.", "label": "Shares Grant Dated Value", "terseLabel": "Shares grant dated value (in Shares)" } } }, "localname": "SharesGrantDatedValue", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "atnf_SharesIssuedDueToImpactOfTransferAgentReconciliation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Shares Issued Due To Impact Of Transfer Agent Reconciliation", "terseLabel": "Shares and warrants issued for Alpha Settlement" } } }, "localname": "SharesIssuedDueToImpactOfTransferAgentReconciliation", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_SharesIssuedFromExerciseOfPrefundedWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of shares issued from exercise of december 2022 pre-funded warrants.", "label": "Shares Issued From Exercise Of Prefunded Warrants", "terseLabel": "Shares issued from exercise of December 2022 pre-funded warrants" } } }, "localname": "SharesIssuedFromExerciseOfPrefundedWarrants", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "atnf_SharesIssuedInConnectionWithOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of share issued in connection with offering.", "label": "Shares Issued In Connection With Offering", "terseLabel": "Shares issued in connection with July 2022 Offering" } } }, "localname": "SharesIssuedInConnectionWithOffering", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "atnf_SharesIssuedInConnectionWithOfferinginShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The shares issued in connection with offering in shares.", "label": "Shares Issued In Connection With Offeringin Shares", "terseLabel": "Shares issued in connection with July 2022 Offering (in Shares)" } } }, "localname": "SharesIssuedInConnectionWithOfferinginShares", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "atnf_SharesIssuedInConnectionWithTheRepaymentOfRelatedPartyLoansAndConvertibleNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of shares issued in connection with the repayment of related party loans and convertible notes.", "label": "Shares Issued In Connection With The Repayment Of Related Party Loans And Convertible Notes", "terseLabel": "Shares issued in connection with the repayment of related party loans and convertible notes (Note 12)" } } }, "localname": "SharesIssuedInConnectionWithTheRepaymentOfRelatedPartyLoansAndConvertibleNotes", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "atnf_SharesIssuedInConnectionsWithOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of shares issued in connection with december 2022 offering.", "label": "Shares Issued In Connections With Offering", "terseLabel": "Shares issued in connection with December 2022 Offering" } } }, "localname": "SharesIssuedInConnectionsWithOffering", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "atnf_SharesIssuedToSettleAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Shares Issued To Settle Accounts Payable", "terseLabel": "Shares issued to settle accounts payable (Note 11)" } } }, "localname": "SharesIssuedToSettleAccountsPayable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "atnf_SharesIssuedToSettleAccountsPayableinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued to settle accounts payable in Shares.", "label": "Shares Issued To Settle Accounts Payablein Shares", "terseLabel": "Shares issued to settle accounts payable (Note 11) (in Shares)" } } }, "localname": "SharesIssuedToSettleAccountsPayableinShares", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "atnf_SharesIssuedToSettleConvertibleDetAndDerivativeLiabilitiesWithAlphaCapitalinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The shares issued to settle convertible debt and derivative liabilities with alpha capital.", "label": "Shares Issued To Settle Convertible Det And Derivative Liabilities With Alpha Capitalin Shares", "terseLabel": "Shares issued to settle convertible debt and derivative liabilities with Alpha Capital (Note 10) (in Shares)" } } }, "localname": "SharesIssuedToSettleConvertibleDetAndDerivativeLiabilitiesWithAlphaCapitalinShares", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "atnf_SharesIssuedUponConversionOf180Debt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued upon conversion of 180 debt.", "label": "Shares Issued Upon Conversion Of180 Debt", "terseLabel": "Shares issued upon conversion of 180 debt (Note 10)" } } }, "localname": "SharesIssuedUponConversionOf180Debt", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "atnf_SharesIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issues", "label": "Shares Issues", "terseLabel": "Shares issues (in Shares)" } } }, "localname": "SharesIssues", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "atnf_SharesOfLicenseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares of license agreement", "label": "Shares Of License Agreement", "terseLabel": "Shares of license agreement" } } }, "localname": "SharesOfLicenseAgreement", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_SimpleInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Simple Interest Rate", "terseLabel": "Simple Interest Rate" } } }, "localname": "SimpleInterestRate", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "percentItemType" }, "atnf_SimpleInterestRatenoncurrent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Simple interest rate.", "label": "Simple Interest Ratenoncurrent", "terseLabel": "Simple interest rate" } } }, "localname": "SimpleInterestRatenoncurrent", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofnoncurrentloanspayableTable" ], "xbrltype": "percentItemType" }, "atnf_SixMonthsPostSigningOfTheFifthOxfordAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Six Months Post Signing Of The Fifth Oxford Agreement Member", "terseLabel": "Six months post signing of the Fifth Oxford Agreement [Member]" } } }, "localname": "SixMonthsPostSigningOfTheFifthOxfordAgreementMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofmakethefollowingpaymentstooxfordTable" ], "xbrltype": "domainItemType" }, "atnf_SpecialVotingShareActivity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of special voting shares activity.", "label": "Special Voting Share Activity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "SpecialVotingShareActivity", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofspecialvotingsharesactivityTable" ], "xbrltype": "sharesItemType" }, "atnf_SpecialVotingShareExchanged": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of special voting shares exchanged.", "label": "Special Voting Share Exchanged", "terseLabel": "Shares exchanged" } } }, "localname": "SpecialVotingShareExchanged", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofspecialvotingsharesactivityTable" ], "xbrltype": "sharesItemType" }, "atnf_SpecialVotingShareIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of special voting shares issued.", "label": "Special Voting Share Issued", "terseLabel": "Shares issued" } } }, "localname": "SpecialVotingShareIssued", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofspecialvotingsharesactivityTable" ], "xbrltype": "sharesItemType" }, "atnf_SpecialVotingSharesActivityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockholders Equity Note Disclosure Text Block.", "label": "Special Voting Shares Activity Text Block", "terseLabel": "Schedule of special voting shares activity" } } }, "localname": "SpecialVotingSharesActivityTextBlock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "atnf_StanfordMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "StanfordMember", "label": "Stanford Member", "terseLabel": "Stanford [Member]" } } }, "localname": "StanfordMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_StockBasedCompensationNote12Abstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Based Compensation Note12 Abstract", "terseLabel": "Stock based compensation (Note 12):" } } }, "localname": "StockBasedCompensationNote12Abstract", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "atnf_StockIssuedDuringPeriodSharebasedCompensationCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Common stock.", "label": "Stock Issued During Period Sharebased Compensation Common Stock", "terseLabel": "Common stock" } } }, "localname": "StockIssuedDuringPeriodSharebasedCompensationCommonStock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "atnf_StockIssuedDuringPeriodSharesIssuedUponExchangeOfCommonStockEquivalentsinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued upon exchange of common stock equivalents.", "label": "Stock Issued During Period Shares Issued Upon Exchange Of Common Stock Equivalentsin Shares", "terseLabel": "Shares issued upon exchange of common stock equivalents (Note 12) (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedUponExchangeOfCommonStockEquivalentsinShares", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "atnf_StockIssuedDuringPeriodSharesReverseStockSplit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of adjustments related to reverse stock-split.", "label": "Stock Issued During Period Shares Reverse Stock Split", "terseLabel": "Adjustments related to reverse stock-split" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplit", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "atnf_StockIssuedDuringPeriodSharesShareBasedCompensationWithCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued stock based compensation with common stock.", "label": "Stock Issued During Period Shares Share Based Compensation With Common Stock", "terseLabel": "Common stock (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationWithCommonStock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "atnf_StockIssuedDuringPeriodValueOfferingCostsAllocatedToWarrantLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of offering costs allocated to warrant liabilities.", "label": "Stock Issued During Period Value Offering Costs Allocated To Warrant Liabilities", "terseLabel": "Offering costs allocated to warrant liabilities (Note 12)" } } }, "localname": "StockIssuedDuringPeriodValueOfferingCostsAllocatedToWarrantLiabilities", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "atnf_StockIssuedDuringPeriodValueSharesIssuedUponExchangeOfCommonStockEquivalents": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of stock issued upon exchange of common stock equivalents.", "label": "Stock Issued During Period Value Shares Issued Upon Exchange Of Common Stock Equivalents", "terseLabel": "Shares issued upon exchange of common stock equivalents (Note 12)" } } }, "localname": "StockIssuedDuringPeriodValueSharesIssuedUponExchangeOfCommonStockEquivalents", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "atnf_StockIssuedDuringPeriodValueStockOptionExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Value Stock Option Exercised", "terseLabel": "Shares issued from exercise of December 2022 pre-funded warrants (in Shares)" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionExercised", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "atnf_StockOptionsExercisableNumberOfShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options exercisable, number of shares.", "label": "Stock Options Exercisable Number Of Share", "terseLabel": "Stock Options Exercisable, Number of Shares" } } }, "localname": "StockOptionsExercisableNumberOfShare", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablestockoptionsTable" ], "xbrltype": "sharesItemType" }, "atnf_StockOptionsExercisableWeightedAverageRemainingsLifeInYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options exercisable weighted average remaining life in years.", "label": "Stock Options Exercisable Weighted Average Remainings Life In Years", "terseLabel": "Stock Options Outstanding, Weighted Average Remaining Life in Years" } } }, "localname": "StockOptionsExercisableWeightedAverageRemainingsLifeInYears", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablestockoptionsTable" ], "xbrltype": "durationItemType" }, "atnf_Stockholder": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholder", "terseLabel": "Stockholder" } } }, "localname": "Stockholder", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "percentItemType" }, "atnf_StockholdersEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Details) [Line Items]" } } }, "localname": "StockholdersEquityDetailsLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "atnf_StockholdersEquityDetailsScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Details) - Schedule of estimated using the black scholes valuation method assumptions [Line Items]" } } }, "localname": "StockholdersEquityDetailsScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsTable" ], "xbrltype": "stringItemType" }, "atnf_StockholdersEquityDetailsScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Details) - Schedule of estimated using the black scholes valuation method assumptions [Table]" } } }, "localname": "StockholdersEquityDetailsScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsTable" ], "xbrltype": "stringItemType" }, "atnf_StockholdersEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Details) [Table]" } } }, "localname": "StockholdersEquityDetailsTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "atnf_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "atnf_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "atnf_TechnologyLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Technology License Member", "terseLabel": "Technology license [Member]" } } }, "localname": "TechnologyLicenseMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "atnf_TotalAdjustments": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Total Adjustments", "totalLabel": "Total adjustments" } } }, "localname": "TotalAdjustments", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "atnf_TotalAmountConverted1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total Amount Converted1", "terseLabel": "Total Amount Converted" } } }, "localname": "TotalAmountConverted1", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "atnf_TotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Member", "terseLabel": "Total [Member]" } } }, "localname": "TotalMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable" ], "xbrltype": "domainItemType" }, "atnf_Totalloanspayable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loans payable.", "label": "Totalloanspayable", "terseLabel": "Non-current portion" } } }, "localname": "Totalloanspayable", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofnoncurrentloanspayableTable" ], "xbrltype": "monetaryItemType" }, "atnf_TradedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Traded stock involves buying and selling of shares in a certain company. If you own certain stocks and shares of a company, it translates to you owning a piece of the firm. A professional or an individual who trades on behalf of a financial firm will be known as a stock trader.", "label": "Traded Stock", "terseLabel": "Traded stock (in Dollars per share)" } } }, "localname": "TradedStock", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails" ], "xbrltype": "perShareItemType" }, "atnf_TwelveMonthsPostSigningOfTheFifthOxfordAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Twelve Months Post Signing Of The Fifth Oxford Agreement Member", "terseLabel": "Twelve months post signing of the Fifth Oxford Agreement [Member]" } } }, "localname": "TwelveMonthsPostSigningOfTheFifthOxfordAgreementMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofmakethefollowingpaymentstooxfordTable" ], "xbrltype": "domainItemType" }, "atnf_TwentyFourthMonthsPostSigningOfTheFifthOxfordAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Twenty Fourth Months Post Signing Of The Fifth Oxford Agreement Member", "terseLabel": "Twenty Fourth months post signing of the Fifth Oxford Agreement [Member]" } } }, "localname": "TwentyFourthMonthsPostSigningOfTheFifthOxfordAgreementMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofmakethefollowingpaymentstooxfordTable" ], "xbrltype": "domainItemType" }, "atnf_TwoSevenPointTwoZeroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Seven Point Two Zero Member", "terseLabel": "27.20 [Member]" } } }, "localname": "TwoSevenPointTwoZeroMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablestockoptionsTable" ], "xbrltype": "domainItemType" }, "atnf_UnitedKingdomFederalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "United Kingdom Federal", "label": "United Kingdom Federal Member", "terseLabel": "United Kingdom Federal [Member]" } } }, "localname": "UnitedKingdomFederalMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "atnf_UnpaidInterestCapitalizedToPrincipal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unpaid Interest Capitalized to Principal.", "label": "Unpaid Interest Capitalized To Principal", "terseLabel": "Unpaid Interest Capitalized to Principal" } } }, "localname": "UnpaidInterestCapitalizedToPrincipal", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "monetaryItemType" }, "atnf_UpfrontFeePaidForIntangibleAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of upfront fee paid for intangible assets.", "label": "Upfront Fee Paid For Intangible Assets", "terseLabel": "Upfront fee paid for intangible assets" } } }, "localname": "UpfrontFeePaidForIntangibleAssets", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_UponSigningOfTheFifthOxfordAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Upon Signing Of The Fifth Oxford Agreement Member", "terseLabel": "Upon signing of the Fifth Oxford Agreement [Member]" } } }, "localname": "UponSigningOfTheFifthOxfordAgreementMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofmakethefollowingpaymentstooxfordTable" ], "xbrltype": "domainItemType" }, "atnf_ValuationAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Valuation Allowance", "terseLabel": "Valuation allowance" } } }, "localname": "ValuationAllowance", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "atnf_VestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of vest rate.", "label": "Vest Rate", "terseLabel": "Vest rate percentage" } } }, "localname": "VestRate", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "atnf_VotingShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Voting Share", "terseLabel": "Voting share (in Shares)" } } }, "localname": "VotingShare", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "atnf_WarrantDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Description", "terseLabel": "Warrant, description" } } }, "localname": "WarrantDescription", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "atnf_WarrantRevalued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "AGP warrant revalued.", "label": "Warrant Revalued", "terseLabel": "Warrant revalued" } } }, "localname": "WarrantRevalued", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_WarrantsExercisableNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Exercisable Number Of Shares", "terseLabel": "Warrants Exercisable Number of Shares" } } }, "localname": "WarrantsExercisableNumberOfShares", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "sharesItemType" }, "atnf_WarrantsExercisableWeightedAverageRemainingLifeInYears": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Exercisable Weighted Average Remaining Life In Years", "terseLabel": "Warrants Exercisable Weighted Average Remaining Life in Years" } } }, "localname": "WarrantsExercisableWeightedAverageRemainingLifeInYears", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "durationItemType" }, "atnf_WarrantsIssuedInConnectionWithPrivateOfferingReclassifiedToDerivativeLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Warrants issued in connection with the private offering, reclassified to derivative liabilities.", "label": "Warrants Issued In Connection With Private Offering Reclassified To Derivative Liabilities", "terseLabel": "Warrants issued in connection with private offering, reclassified to derivative liabilities (Note 8)" } } }, "localname": "WarrantsIssuedInConnectionWithPrivateOfferingReclassifiedToDerivativeLiabilities", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "atnf_WarrantsIssuedInConnectionWithTheFinancing": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of warrants issued in connection with the private offering of shares.", "label": "Warrants Issued In Connection With The Financing", "terseLabel": "Warrants issued in connection with the financing" } } }, "localname": "WarrantsIssuedInConnectionWithTheFinancing", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "atnf_WarrantsIssuedRelatesToAlphaSettlement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Warrants issued relates to Alpha settlement.", "label": "Warrants Issued Relates To Alpha Settlement", "terseLabel": "Warrants issued relates to Alpha settlement" } } }, "localname": "WarrantsIssuedRelatesToAlphaSettlement", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "atnf_WarrantsIssuedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants issued shares.", "label": "Warrants Issued Shares", "terseLabel": "Purchase of aggregate shares (in Shares)" } } }, "localname": "WarrantsIssuedShares", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "sharesItemType" }, "atnf_WarrantsOfExercisableShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants of exercisable shares.", "label": "Warrants Of Exercisable Shares", "terseLabel": "Aggregate amount (in Shares)" } } }, "localname": "WarrantsOfExercisableShares", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "sharesItemType" }, "atnf_WarrantsPurchasePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants purchase price", "label": "Warrants Purchase Price", "terseLabel": "Warrants exercise price (in Shares)" } } }, "localname": "WarrantsPurchasePrice", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "atnf_WeightedAverageExercisePriceCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Cancelled.", "label": "Weighted Average Exercise Price Cancelled", "terseLabel": "Weighted Average Exercise Price, Cancelled" } } }, "localname": "WeightedAverageExercisePriceCancelled", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "perShareItemType" }, "atnf_WeightedAverageExercisePriceExercisableEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Exercisable ending", "label": "Weighted Average Exercise Price Exercisable Ending", "terseLabel": "Weighted Average Exercise Price, Exercisable ending" } } }, "localname": "WeightedAverageExercisePriceExercisableEnding", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "perShareItemType" }, "atnf_WeightedAverageExercisePriceExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Exercised.", "label": "Weighted Average Exercise Price Exercised", "terseLabel": "Weighted Average Exercise Price, Exercised" } } }, "localname": "WeightedAverageExercisePriceExercised", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "perShareItemType" }, "atnf_WeightedAverageExercisePriceOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The per share weighted average exercise price.", "label": "Weighted Average Exercise Price Outstanding", "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending balance", "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning balance" } } }, "localname": "WeightedAverageExercisePriceOutstanding", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "perShareItemType" }, "atnf_WeightedAverageExercisesPriceIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Issued.", "label": "Weighted Average Exercises Price Issued", "terseLabel": "Weighted Average Exercise Price, Issued" } } }, "localname": "WeightedAverageExercisesPriceIssued", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "perShareItemType" }, "atnf_WeightedAverageRemainingTerm1ExercisableEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Term1 Exercisable Ending", "terseLabel": "Weighted Average Remaining Term (in Years), Exercisable ending" } } }, "localname": "WeightedAverageRemainingTerm1ExercisableEnding", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "durationItemType" }, "atnf_WeightedAverageRemainingTerm1Exercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Term1 Exercised", "terseLabel": "Weighted Average Remaining Term (in Years), Exercised" } } }, "localname": "WeightedAverageRemainingTerm1Exercised", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "durationItemType" }, "atnf_WeightedAverageRemainingTerm1Expired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Term1 Expired", "terseLabel": "Weighted Average Remaining Term (in Years), Expired" } } }, "localname": "WeightedAverageRemainingTerm1Expired", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "durationItemType" }, "atnf_WeightedAverageRemainingTerm1Forfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Term1 Forfeited", "terseLabel": "Weighted Average Remaining Term (in Years), Forfeited" } } }, "localname": "WeightedAverageRemainingTerm1Forfeited", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "durationItemType" }, "atnf_WeightedAverageRemainingTerm1Granted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of granted options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Term1 Granted", "terseLabel": "Weighted Average Remaining Term (in Years), Granted" } } }, "localname": "WeightedAverageRemainingTerm1Granted", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "durationItemType" }, "atnf_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of working capital deficit.", "label": "Working Capital Deficit", "terseLabel": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/GoingConcernandManagementsPlansDetails" ], "xbrltype": "monetaryItemType" }, "atnf_YearlyPaymentToAConsultant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of yearly payment to a consultant.", "label": "Yearly Payment To AConsultant", "terseLabel": "First amendment company paid" } } }, "localname": "YearlyPaymentToAConsultant", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "atnf_YissumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "YissumMember", "label": "Yissum Member", "terseLabel": "Yissum [Member]" } } }, "localname": "YissumMember", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "atnf_aggregateAccruedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "aggregate Accrued Interest", "terseLabel": "Aggregate accrued interest" } } }, "localname": "aggregateAccruedInterest", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_aggregateAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount.", "label": "aggregate Amount", "terseLabel": "Aggregate amount" } } }, "localname": "aggregateAmount", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "atnf_incurredExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of incurred expenses.", "label": "incurred Expenses", "terseLabel": "Incurred expenses" } } }, "localname": "incurredExpenses", "nsuri": "http://180lifesciences.com/20221231", "presentation": [ "http://180lifesciences.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r674", "r675", "r676" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r674", "r675", "r676" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r674", "r675", "r676" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r674", "r675", "r676" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r677" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r678" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r679" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r674", "r675", "r676" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r671" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r673" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://180lifesciences.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r709" ], "lang": { "en-us": { "role": { "documentation": "Leader of board of directors.", "label": "Board of Directors Chairman [Member]", "terseLabel": "Board of Directors [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r709" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of chief executive officer.", "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r709" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of chief financial officer.", "label": "Chief Financial Officer [Member]", "terseLabel": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r247", "r512", "r513", "r516", "r517", "r551", "r636", "r641", "r730", "r733", "r734", "r773", "r774", "r775" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r247", "r512", "r513", "r516", "r517", "r551", "r636", "r641", "r730", "r733", "r734", "r773", "r774", "r775" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r709" ], "lang": { "en-us": { "role": { "documentation": "Person serving on board of directors.", "label": "Director [Member]", "terseLabel": "Former officers, directors [Member]", "verboseLabel": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_FinancingReceivableWriteoffAfterRecoveryToAverageOutstandingPercent": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Percentage of writeoff after recovery to average financing receivables outstanding.", "label": "Financing Receivable, Writeoff after Recovery to Average Outstanding, Percent", "terseLabel": "Financing Receivable, Writeoff after Recovery to Average Outstanding, Percent" } } }, "localname": "FinancingReceivableWriteoffAfterRecoveryToAverageOutstandingPercent", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "srt_MaximumMember": { "auth_ref": [ "r328", "r329", "r330", "r331", "r449", "r585", "r612", "r637", "r638", "r656", "r665", "r670", "r735", "r756", "r757", "r758", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "http://180lifesciences.com/role/ScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsTable", "http://180lifesciences.com/role/ScheduleofoptionpricingmodelsTable", "http://180lifesciences.com/role/StockholdersEquityDetails", "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r328", "r329", "r330", "r331", "r449", "r585", "r612", "r637", "r638", "r656", "r665", "r670", "r735", "r756", "r757", "r758", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "http://180lifesciences.com/role/ScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsTable", "http://180lifesciences.com/role/ScheduleofoptionpricingmodelsTable", "http://180lifesciences.com/role/StockholdersEquityDetails", "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of officer.", "label": "Officer [Member]", "terseLabel": "Officer [Member]" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r328", "r329", "r330", "r331", "r409", "r449", "r470", "r471", "r472", "r561", "r585", "r612", "r637", "r638", "r656", "r665", "r670", "r727", "r735", "r757", "r758", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "http://180lifesciences.com/role/ScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsTable", "http://180lifesciences.com/role/ScheduleofoptionpricingmodelsTable", "http://180lifesciences.com/role/StockholdersEquityDetails", "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r328", "r329", "r330", "r331", "r409", "r449", "r470", "r471", "r472", "r561", "r585", "r612", "r637", "r638", "r656", "r665", "r670", "r727", "r735", "r757", "r758", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "http://180lifesciences.com/role/ScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsTable", "http://180lifesciences.com/role/ScheduleofoptionpricingmodelsTable", "http://180lifesciences.com/role/StockholdersEquityDetails", "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r450", "r707", "r772" ], "lang": { "en-us": { "role": { "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.", "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r261", "r450", "r681", "r707" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable", "http://180lifesciences.com/role/ScheduleofprepaidexpensesTable", "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.", "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r261", "r450", "r681", "r682", "r707" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable", "http://180lifesciences.com/role/ScheduleofprepaidexpensesTable", "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r709", "r751" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r13", "r669" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableOtherCurrent": { "auth_ref": [ "r13" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable, Other, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableOtherCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Accrued Bonus" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrentAndNoncurrent": { "auth_ref": [ "r171", "r190" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.", "label": "Accrued Bonuses", "terseLabel": "Accrued bonus payable" } } }, "localname": "AccruedBonusesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedExchangeFeeRebateCurrent": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates of an exchange fee some mutual funds impose on shareholders if they exchange (transfer) to another fund within the same fund group. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Exchange Fee Rebate, Current", "terseLabel": "Accrued fees (in Euro)" } } }, "localname": "AccruedExchangeFeeRebateCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxes": { "auth_ref": [ "r1", "r3", "r122", "r167", "r184" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.", "label": "Accrued Income Taxes", "terseLabel": "Taxes" } } }, "localname": "AccruedIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Annual license maintenance fee" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r29", "r30", "r31", "r217", "r606", "r617", "r618" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r28", "r31", "r136", "r544", "r613", "r614", "r690", "r691", "r692", "r704", "r705", "r706" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r8", "r669" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r476", "r477", "r478", "r704", "r705", "r706", "r747" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r90", "r95", "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature", "terseLabel": "Shares issued to settle convertible debt and derivative liabilities with Alpha Capital (Note 10)" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r112", "r113", "r452" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdministrativeFeesExpense": { "auth_ref": [ "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.", "label": "Administrative Fees Expense", "terseLabel": "license maintenance fee" } } }, "localname": "AdministrativeFeesExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r474" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, after Tax", "terseLabel": "Unvested Restricted Stock, Total unrecognized expense remaining" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofrestrictedstocksharesgrantedandoutstandingTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r42", "r51", "r157", "r363" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r36", "r363", "r539", "r697" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortized interest expense" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r363", "r539", "r654", "r655", "r697" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r51", "r70", "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmountOfImpairmentToCarryingAmountOfRegulatoryAssets": { "auth_ref": [ "r201" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Discloses the amount of any reduction to the carrying amounts of regulated assets that result from impairment (for example, rate actions of a regulator).", "label": "Amount of Impairment to Carrying Amount of Regulatory Assets", "terseLabel": "Carrying amount" } } }, "localname": "AmountOfImpairmentToCarryingAmountOfRegulatoryAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total potentially dilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofantidilutivecommonsharesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r165", "r183", "r212", "r242", "r284", "r286", "r288", "r294", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r512", "r516", "r524", "r669", "r731", "r732", "r754" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r207", "r218", "r242", "r294", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r512", "r516", "r524", "r669", "r731", "r732", "r754" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender": { "auth_ref": [ "r179", "r180", "r196", "r481" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of bad debt reserves for tax purposes of qualified lenders excluded in calculating deferred taxes.", "label": "Bad Debt Reserve, Tax Purpose of Qualified Lender", "terseLabel": "Bad debt expenses" } } }, "localname": "BadDebtReserveForTaxPurposesOfQualifiedLender", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r510", "r659", "r662" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r129", "r130", "r510", "r659", "r662" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r131", "r132", "r133" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business combination warrants value" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business.", "label": "Cash Acquired in Excess of Payments to Acquire Business", "terseLabel": "Cash payments" } } }, "localname": "CashAcquiredInExcessOfPaymentsToAcquireBusiness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r47", "r53", "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash - End of Period", "periodStartLabel": "Cash - Beginning of Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r47", "r156" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (Decrease) Increase In Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r683" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash Flows From Operating Activities" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r214", "r215", "r216", "r242", "r264", "r265", "r268", "r270", "r274", "r275", "r294", "r332", "r334", "r335", "r336", "r339", "r340", "r369", "r370", "r373", "r377", "r384", "r524", "r639", "r680", "r699", "r708" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price per share (in Dollars per share)", "verboseLabel": "Warrants exercise price (in Dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Purchase of shares of common stock (in Shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofantidilutivecommonsharesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants Outstanding Number of Shares" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightUnissued": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.", "label": "Class of Warrant or Right, Unissued", "terseLabel": "Warrants shares (in Shares)" } } }, "localname": "ClassOfWarrantOrRightUnissued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r23", "r173", "r189" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r82", "r325", "r326", "r635", "r729" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common shares (in Shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockConvertibleConversionPriceDecrease": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision.", "label": "Common Stock, Convertible, Conversion Price, Decrease", "terseLabel": "Common stock price (in Dollars per share)" } } }, "localname": "CommonStockConvertibleConversionPriceDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockConvertibleConversionPriceIncrease": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.", "label": "Common Stock, Convertible, Conversion Price, Increase", "terseLabel": "Conversion price (in Dollars per share)" } } }, "localname": "CommonStockConvertibleConversionPriceIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r704", "r705", "r747" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "netLabel": "Par value per share (in Dollars per share)", "terseLabel": "Common stock, par value (in Dollars per share)", "verboseLabel": "Common stock, par value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/BusinessOrganizationandNatureofOperationsDetails", "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Common stock shares authorized (in Shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r90" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r7", "r669" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 100,000,000 shares authorized; 3,746,906 and 1,701,799 shares issued and outstanding at December 31, 2022 and 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensatingBalanceAmount": { "auth_ref": [ "r209" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability.", "label": "Compensating Balance, Amount", "terseLabel": "Compensation amount" } } }, "localname": "CompensatingBalanceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndBenefitsTrust": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of a trust established to hold the stock of an employee compensation and benefits plan as of the balance sheet date.", "label": "Compensation and Benefits Trust", "terseLabel": "Compensation and Benefits Trust" } } }, "localname": "CompensationAndBenefitsTrust", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r32", "r223", "r225", "r232", "r603", "r608" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r135", "r644" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r56", "r57", "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Issued", "negatedLabel": "Conversions to Common Stock" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r56", "r57", "r58" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Conversions to Common Stock (in Shares)", "verboseLabel": "Common Shares Issued (in Shares)" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable", "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r2", "r169", "r186" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "terseLabel": "Common Shares Issued" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r84", "r341", "r342", "r353", "r354", "r355", "r359", "r360", "r361", "r362", "r363", "r651", "r652", "r653", "r654", "r655" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Schedule of convertible notes payable activity" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r2", "r169", "r185", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable", "periodEndLabel": "12/31/21 Principal Balance", "periodStartLabel": "01/01/21 Principal Balance" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r0", "r166", "r182", "r198" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]", "terseLabel": "Convertible Notes Payable [Member]", "verboseLabel": "Convertible Notes [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofderivativeliabilitiesTable", "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpensesRelatedParty": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.", "label": "Costs and Expenses, Related Party", "terseLabel": "Principal amount" } } }, "localname": "CostsAndExpensesRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditRiskDerivativeLiabilitiesAtFairValue": { "auth_ref": [ "r147" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of credit risk derivative liability.", "label": "Credit Risk Derivative Liabilities, at Fair Value", "terseLabel": "Fair value of derivative liabilities" } } }, "localname": "CreditRiskDerivativeLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRefundableFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of proceeds that had been received in revenue related transactions that are refundable to the customers and do not meet the criteria for revenue recognition (for example, refundable membership fees).", "label": "Customer Refundable Fees", "terseLabel": "Non-refundable license fees" } } }, "localname": "CustomerRefundableFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "auth_ref": [ "r56", "r58" ], "lang": { "en-us": { "role": { "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.", "label": "Debt Conversion Description [Axis]" } } }, "localname": "DebtConversionByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r56", "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Common stock issued upon conversion of 180 debt" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentIssuanceDateDayMonthAndYear": { "auth_ref": [ "r56", "r58" ], "lang": { "en-us": { "role": { "documentation": "Date the financial instrument was issued in exchange for the original debt being converted in a noncash or part noncash transaction, in YYYY-MM-DD format.", "label": "Debt Conversion, Converted Instrument, Issuance Date", "terseLabel": "Effective Date" } } }, "localname": "DebtConversionConvertedInstrumentIssuanceDateDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "dateItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r56", "r58" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Shares issued upon conversion of KBL debt (Note 10) (in Shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "auth_ref": [ "r56", "r58" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued", "terseLabel": "Aggregate shares of common stock (in Shares)" } } }, "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Conversion [Line Items]" } } }, "localname": "DebtConversionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofderivativeliabilitiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionTable": { "auth_ref": [ "r56", "r58" ], "lang": { "en-us": { "role": { "documentation": "A table that contains information on an original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion [Table]" } } }, "localname": "DebtConversionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofderivativeliabilitiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r88", "r240", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r357", "r364", "r365", "r367" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "CONVERTIBLE NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "auth_ref": [ "r2" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the total principal payments made during the annual reporting period.", "label": "Debt Instrument, Annual Principal Payment", "periodEndLabel": "Principal ending balance", "periodStartLabel": "Principal beginning balance" } } }, "localname": "DebtInstrumentAnnualPrincipalPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r0", "r1", "r2", "r166", "r169", "r182", "r247", "r341", "r342", "r343", "r344", "r345", "r347", "r353", "r354", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r540", "r651", "r652", "r653", "r654", "r655", "r700" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable", "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable", "http://180lifesciences.com/role/ScheduleofnoncurrentloanspayableTable", "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r85", "r343" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price (in Dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "auth_ref": [ "r20", "r91", "r92", "r93" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for debt instrument.", "label": "Debt Instrument, Convertible, Terms of Conversion Feature", "terseLabel": "Convertible promissory note, description" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r158", "r160", "r341", "r540", "r652", "r653" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r355", "r523", "r652", "r653" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value amount" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r700" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest", "terseLabel": "Accrued interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r19", "r158", "r368", "r540" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Interest percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r19", "r342" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Simple Interest Rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentIssuanceDate1": { "auth_ref": [ "r21", "r735" ], "lang": { "en-us": { "role": { "documentation": "Date the debt instrument was issued, in YYYY-MM-DD format.", "label": "Debt Instrument, Issuance Date", "terseLabel": "Effective Date" } } }, "localname": "DebtInstrumentIssuanceDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r219", "r651", "r748" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity Date (as amended, if applicable)", "verboseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "http://180lifesciences.com/role/LoansPayableDetails", "http://180lifesciences.com/role/ScheduleofconvertiblenotespayableactivityTable", "http://180lifesciences.com/role/ScheduleofconvertiblenotespayablerelatedpartiesTable" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r22", "r247", "r341", "r342", "r343", "r344", "r345", "r347", "r353", "r354", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r540", "r651", "r652", "r653", "r654", "r655", "r700" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable", "http://180lifesciences.com/role/ScheduleofnoncurrentloanspayableTable", "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r22", "r177" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "negatedLabel": "Principal Repaid in Cash" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r22", "r91", "r92", "r93", "r94", "r157", "r158", "r160", "r178", "r247", "r341", "r342", "r343", "r344", "r345", "r347", "r353", "r354", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r366", "r540", "r651", "r652", "r653", "r654", "r655", "r700" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableofcurrentportionTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1": { "auth_ref": [ "r753" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of net gain (loss) on settlement of other claims for entities in bankruptcy, reported as a reorganization item.", "label": "Debtor Reorganization Items, Gain (Loss) on Settlement of Other Claims, Net", "terseLabel": "Gain (loss) on settlement of liabilities" } } }, "localname": "DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.", "label": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage", "terseLabel": "Percentage of accrual salary" } } }, "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued": { "auth_ref": [ "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total fair value of shares issued during the period under a deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued", "terseLabel": "Fair Value of Shares Issued" } } }, "localname": "DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsAndOtherAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost assets and assets classified as other.", "label": "Deferred Costs and Other Assets", "terseLabel": "Deferred tax benefits" } } }, "localname": "DeferredCostsAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofincometaxbenefitsprovisionTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r702", "r743", "r744" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofincometaxbenefitsprovisionTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r128", "r702", "r743" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "International" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofincometaxbenefitsprovisionTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r4", "r5", "r168", "r181", "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r484", "r485" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Net income tax benefit" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofincometaxbenefitsprovisionTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r715" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Placement agent fees and offering expenses" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r702", "r743", "r744" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofincometaxbenefitsprovisionTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r492" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r741" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Deferred tax assets and liabilities" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r126", "r742" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r126", "r742" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r126", "r742" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Stock compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r493" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Provision for valuation allowance of deferred tax assets net" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r120", "r741" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedLabel": "Deferred tax assets and liabilities, net" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpense": { "auth_ref": [ "r126", "r742" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.", "label": "Deferred Tax Liabilities, Deferred Expense", "negatedLabel": "Technology license" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts": { "auth_ref": [ "r126", "r742" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from patent costs.", "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs", "terseLabel": "Past patent costs" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": { "auth_ref": [ "r126", "r742" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.", "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs", "negatedLabel": "Acquired in-process research and development" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r126", "r742" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositLiabilitiesAccruedInterest": { "auth_ref": [ "r171" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued but unpaid interest on deposit liabilities.", "label": "Deposit Liabilities, Accrued Interest", "terseLabel": "Accrued interest" } } }, "localname": "DepositLiabilitiesAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails", "http://180lifesciences.com/role/ScheduleofderivativeliabilitiesTable", "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r746" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedLabel": "Gain on settlement of liabilities, net" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r141", "r142", "r144", "r146", "r643" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails", "http://180lifesciences.com/role/ScheduleofderivativeliabilitiesTable", "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r149", "r518" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "DERIVATIVE LIABILITIES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r220" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "terseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r137", "r138", "r139", "r140", "r148", "r246" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Liabilities and Convertible Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Abstract]" } } }, "localname": "DisclosureTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DividendsShareBasedCompensationCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for award under share-based payment arrangement.", "label": "Dividend, Share-Based Payment Arrangement, Cash", "terseLabel": "Cash payment" } } }, "localname": "DividendsShareBasedCompensationCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r233", "r253", "r254", "r255", "r256", "r257", "r262", "r264", "r268", "r269", "r270", "r272", "r521", "r522", "r604", "r609", "r645" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic and Diluted Net Loss per Common Share (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r233", "r253", "r254", "r255", "r256", "r257", "r264", "r268", "r269", "r270", "r272", "r521", "r522", "r604", "r609", "r645" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Basic and Diluted Net Loss per Common Share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r61", "r62" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r750" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of Exchange Rate Changes on Cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Taxable income" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r244", "r487", "r504" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "US Federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofunitedstatesfederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r740", "r745" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofunitedstatesfederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": { "auth_ref": [ "r740", "r745" ], "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.", "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofunitedstatesfederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r740", "r745" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "terseLabel": "Goodwill impairment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofunitedstatesfederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent", "terseLabel": "Change in the fair value of derivatives and accrued issuable equity" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofunitedstatesfederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r739", "r740" ], "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "terseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofunitedstatesfederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r740", "r745" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State and provincial taxes, net of federal benefits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofunitedstatesfederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesOther": { "auth_ref": [ "r740", "r745" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other income tax contingencies.", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxContingenciesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofunitedstatesfederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": { "auth_ref": [ "r740", "r745" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent", "terseLabel": "Difference between domestic and foreign federal rates" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofunitedstatesfederalstatutoryrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable": { "order": 4.0, "parentTag": "atnf_AccruedLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employee Benefits and Share-Based Compensation", "terseLabel": "Employee and director compensation" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r90", "r205", "r227", "r228", "r229", "r248", "r249", "r250", "r252", "r258", "r260", "r273", "r295", "r386", "r476", "r477", "r478", "r499", "r500", "r520", "r529", "r530", "r531", "r532", "r533", "r535", "r544", "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails", "http://180lifesciences.com/role/ShareholdersEquityType2or3", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Beneficial ownership interest" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Issued warrants (in Shares)" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r51", "r89" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 7.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of derivative liabilities" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionpricingmodelsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueConcentrationOfRiskTable": { "auth_ref": [ "r152", "r153", "r154", "r155" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. Such disclosure may also include quantitative information about the market risks of financial instruments that is consistent with the way the Company manages or adjusts those risks.", "label": "Fair Value, Concentration of Risk [Table]" } } }, "localname": "FairValueConcentrationOfRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionpricingmodelsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueConcentrationOfRiskTextBlock": { "auth_ref": [ "r152", "r153", "r154", "r155" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.", "label": "Fair Value, Concentration of Risk [Table Text Block]", "terseLabel": "Schedule of option pricing models" } } }, "localname": "FairValueConcentrationOfRiskTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueHedgeLiabilitiesAtFairValue": { "auth_ref": [ "r142" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of all derivative liabilities designated as fair value hedging instruments.", "label": "Fair Value Hedge Liabilities", "terseLabel": "Fair value of derivative liabilities" } } }, "localname": "FairValueHedgeLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleoffairvalueofLevel3derivativeliabilitiesexceptthePublicSpecialPurposeAcquisitionCompaniesSPACwarrantsasdefinedbelowwhichareLevel1derivativeliabilitiesthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of fair value of Level 3 derivative liabilities (except the Public Special Purpose Acquisition Companies (\u201cSPAC\u201d) warrants as defined below, which are Level 1 derivative liabilities that are measured at fair value on a recurring basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Fair Value, Net Asset (Liability)", "terseLabel": "Fair market value of assets" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r291", "r292", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r366", "r382", "r518", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r648", "r710", "r711", "r712", "r765", "r766", "r767", "r768", "r769", "r770", "r771" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r211", "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r76" ], "calculation": { "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r76" ], "calculation": { "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r76" ], "calculation": { "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r76" ], "calculation": { "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r76" ], "calculation": { "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r318", "r319", "r320", "r321", "r587", "r588" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails", "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable", "http://180lifesciences.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r74", "r588" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross asset value" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r71", "r73" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails", "http://180lifesciences.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r74", "r587" ], "calculation": { "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Net carrying value", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleoffutureamortizationrelatedtointangibleassetsTable", "http://180lifesciences.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Remaining amortization period in years" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r525", "r526", "r527", "r528" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign currency transaction gain loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "auth_ref": [ "r697" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "terseLabel": "Loss on IP R&D impairment" } } }, "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r728" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "terseLabel": "Gain on settlement of liabilities" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r51", "r86", "r87" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Loss on extinguishment of convertible notes payable, net", "verboseLabel": "Loss on Extinguishment of Convertible Notes" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement", "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r210", "r304", "r601", "r650", "r669", "r716", "r723" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance at ending", "periodStartLabel": "Balance at beginning", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet", "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Loss on goodwill impairment" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r316", "r317", "r650" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r311" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r51", "r305", "r310", "r316", "r650" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedLabel": "Loss on goodwill impairment", "terseLabel": "Balance before impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement", "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLossNetOfTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of loss recognized that results from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss, Net of Tax", "negatedLabel": "Impairment of goodwill" } } }, "localname": "GoodwillImpairmentLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable" ], "xbrltype": "stringItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairedIntangibleAssetDescription": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "A description of the finite or indefinite-lived intangible asset (excluding goodwill) that is impaired.", "label": "Impaired Intangible Asset, Description", "terseLabel": "IP R&D asset balance description" } } }, "localname": "ImpairedIntangibleAssetDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r51", "r78" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "negatedLabel": "Impairment of IP R&D assets", "terseLabel": "Impairment of goodwill" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow", "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r51", "r79", "r81" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Impairment of IP R&D assets" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r243", "r503" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofincometaxdomesticandinternationalcomponentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r34", "r163", "r174", "r193", "r284", "r285", "r287", "r289", "r605", "r647" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss Before Income Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r243", "r503" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "International" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofincometaxdomesticandinternationalcomponentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r244", "r488", "r489", "r496", "r501", "r505", "r507", "r508", "r509" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r245", "r259", "r260", "r283", "r486", "r502", "r506", "r610" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r226", "r482", "r483", "r489", "r490", "r495", "r497" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r55" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid during the period for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r50" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r50" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r50" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred tax liability" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "auth_ref": [ "r696" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).", "label": "Increase (Decrease) in Derivative Liabilities", "terseLabel": "Change in fair value of derivative liabilities" } } }, "localname": "IncreaseDecreaseInDerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInFairValueOfPriceRiskFairValueHedgingInstruments1": { "auth_ref": [ "r143" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) related to the fair value of price risk derivatives designated as fair value hedging instruments, as offset by the gain (loss) on the hedged item to the extent that the fair value hedge is determined to be effective.", "label": "Increase (Decrease) in Fair Value of Price Risk Fair Value Hedging Instruments", "terseLabel": "SPAC warrants" } } }, "localname": "IncreaseDecreaseInFairValueOfPriceRiskFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r50" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accrued expenses \u2013 related parties" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r50" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS AND IMPAIRMENT OF LONG-LIVED ASSETS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r69", "r72" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r159", "r176", "r230", "r282", "r538" ], "calculation": { "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable": { "order": 6.0, "parentTag": "atnf_AccruedLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense [Member]" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense, Related Party", "terseLabel": "Interest expense related party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r234", "r237", "r238" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r687" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable", "terseLabel": "Interest accruing" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedBalancePrincipalAmount": { "auth_ref": [ "r197", "r622" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For investments which are quantified by principal amount, the principle balance held at close of period.", "label": "Investment Owned, Balance, Principal Amount", "terseLabel": "Aggregate principal balance" } } }, "localname": "InvestmentOwnedBalancePrincipalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r619", "r620", "r621", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r619", "r620", "r621", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r51" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Shares issued for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r38" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees", "terseLabel": "Legal expenses" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r16", "r242", "r294", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r513", "r516", "r517", "r524", "r646", "r731", "r754", "r755" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r12", "r170", "r188", "r669", "r701", "r713", "r749" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r18", "r208", "r242", "r294", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r513", "r516", "r517", "r524", "r669", "r731", "r754", "r755" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity", "verboseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r737" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "Licensed patents [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "domainItemType" }, "us-gaap_LoansHeldForSaleMaturityDate": { "auth_ref": [ "r748" ], "lang": { "en-us": { "role": { "documentation": "Maturity date of loan held for sale, in YYYY-MM-DD format.", "label": "Loans Held-for-sale, Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "LoansHeldForSaleMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofnoncurrentloanspayableTable" ], "xbrltype": "dateItemType" }, "us-gaap_LoansPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans Payable [Abstract]" } } }, "localname": "LoansPayableAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current", "periodEndLabel": "Less: Principal ending balance loans payable \u2013 current portion", "periodStartLabel": "Less: Principal beginning balance loans payable \u2013 current portion", "terseLabel": "Loans payable - current portion" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet", "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.", "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate", "terseLabel": "Interest percentage" } } }, "localname": "LongTermDebtPercentageBearingFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "periodEndLabel": "Principal ending balance Loans payable \u2013 non-current portion", "periodStartLabel": "Principal beginning balance Loans payable \u2013 non-current portion" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r22", "r83" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ManagementFeeExpense": { "auth_ref": [ "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).", "label": "Management Fee Expense", "terseLabel": "Anniversaries amount" } } }, "localname": "ManagementFeeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ManagementFeePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of the unpaid portion of the fee payable to the managing member or general partner for management of the fund or trust.", "label": "Management Fee Payable", "terseLabel": "Payable Fees (in Euro)" } } }, "localname": "ManagementFeePayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Fair market value" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r276", "r281" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "BUSINESS ORGANIZATION AND NATURE OF OPERATIONS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/BusinessOrganizationandNatureofOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInContinuingOperations": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.", "label": "Net Cash Provided by (Used in) Continuing Operations", "terseLabel": "Cash used in operations" } } }, "localname": "NetCashProvidedByUsedInContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/GoingConcernandManagementsPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r236" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided By Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r47", "r49", "r52" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Used In Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r35", "r52", "r175", "r192", "r206", "r221", "r224", "r229", "r242", "r251", "r253", "r254", "r255", "r256", "r259", "r260", "r266", "r284", "r285", "r287", "r289", "r294", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r522", "r524", "r647", "r731" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow", "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r253", "r254", "r255", "r256", "r262", "r263", "r267", "r270", "r284", "r285", "r287", "r289", "r647" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net Loss Attributable to Common Stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r41" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total Other Expense, Net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r56", "r57", "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Notes Issued", "terseLabel": "Bridge notes issued" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r284", "r285", "r287", "r289", "r647" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss From Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r125" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commitment classified as other to be paid in remainder of current fiscal year.", "label": "Other Commitment, to be Paid, Remainder of Fiscal Year", "terseLabel": "Financing transaction of agreement" } } }, "localname": "OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "auth_ref": [ "r67", "r231", "r529", "r534", "r535", "r602", "r607", "r690", "r691" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Tax", "terseLabel": "Other comprehensive gain (loss)" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "auth_ref": [ "r27", "r29" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r33", "r90", "r222", "r225", "r231", "r529", "r534", "r535", "r602", "r607", "r690", "r691" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax [Abstract]", "terseLabel": "Other Comprehensive (Loss) Income:", "verboseLabel": "Comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement", "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]", "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/PrepaidExpensesandOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherDepreciationAndAmortization": { "auth_ref": [ "r38", "r51", "r80" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "Other Depreciation and Amortization", "terseLabel": "Amortization of intangibles" } } }, "localname": "OtherDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r40", "r195" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "netLabel": "Amount spend", "terseLabel": "Oxford agreements expenses", "verboseLabel": "Interest expenses" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "http://180lifesciences.com/role/PrepaidExpensesandOtherCurrentAssetsDetails", "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "Other General and Administrative Expense", "terseLabel": "General and administrative expenses - related parties" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r194" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other expense" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (Expenses) Income:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OtherPaymentsToAcquireBusinesses": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.", "label": "Other Payments to Acquire Businesses", "terseLabel": "Amount Due (excluding VAT)" } } }, "localname": "OtherPaymentsToAcquireBusinesses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofmakethefollowingpaymentstooxfordTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r688", "r714" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid balances" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherResearchAndDevelopmentExpense": { "auth_ref": [ "r115" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other research and development expense.", "label": "Other Research and Development Expense", "terseLabel": "Research and development expenses" } } }, "localname": "OtherResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromHedgeFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payments for (Proceeds from) Hedge, Financing Activities [Abstract]", "terseLabel": "Cash Flows From Financing Activities" } } }, "localname": "PaymentsForProceedsFromHedgeFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for Rent", "terseLabel": "Rent (in Euro)" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class A [Member]", "terseLabel": "Class C Preferred Stock", "verboseLabel": "Class A preferred stock [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Preferred Class B [Member]", "terseLabel": "Class K Preferred Stock" } } }, "localname": "PreferredClassBMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred Stock, Convertible, Conversion Price", "terseLabel": "Conversion price per share (in Dollars per share)" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r6", "r369" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock shares authorized (in Shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r6", "r369" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "verboseLabel": "Preferred shares issued (in Shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r6", "r669" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 5,000,000 shares authorized; (see designations and shares authorized for Series A, Class C and Class K preferred stock)" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r689" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "verboseLabel": "Total" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet", "http://180lifesciences.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidRent": { "auth_ref": [ "r642", "r649", "r714" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Rent", "terseLabel": "Repaid amount" } } }, "localname": "PrepaidRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r45" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from sale of December 2022 common stock and common stock warrants" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r694" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "New Issuances" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r45" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Shares issued for cash, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Offering expenses" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoanOriginations1": { "auth_ref": [ "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.", "label": "Proceeds from Loan Originations", "terseLabel": "Cash proceed" } } }, "localname": "ProceedsFromLoanOriginations1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/LoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductLiabilityContingencyLossExposureInExcessOfAccrualBestEstimate": { "auth_ref": [ "r327", "r330" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Best estimate of the reasonably possible loss exposure in excess of the amount accrued for damages pertaining to a specified product.", "label": "Product Liability Contingency, Loss Exposure in Excess of Accrual, Best Estimate", "terseLabel": "Compensatory damages in excess" } } }, "localname": "ProductLiabilityContingencyLossExposureInExcessOfAccrualBestEstimate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r199", "r200" ], "calculation": { "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable": { "order": 2.0, "parentTag": "atnf_AccruedLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional Fees", "terseLabel": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/RelatedPartiesDetails", "http://180lifesciences.com/role/ScheduleofaccruedexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r206", "r221", "r224", "r235", "r242", "r251", "r259", "r260", "r284", "r285", "r287", "r289", "r294", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r511", "r514", "r515", "r522", "r524", "r605", "r647", "r667", "r668", "r692", "r731" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/GoingConcernandManagementsPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r433", "r547", "r548" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r203", "r547", "r548", "r752" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": { "auth_ref": [ "r204", "r213", "r541", "r542", "r543", "r546" ], "lang": { "en-us": { "role": { "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.", "label": "Related Party Transaction, Description of Transaction", "terseLabel": "Related party transaction, description" } } }, "localname": "RelatedPartyTransactionDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party", "terseLabel": "Bad debt expense - related parties" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r433", "r547", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r752" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/RelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r545", "r546", "r548", "r549", "r550" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTIES" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/RelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r46" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt", "negatedLabel": "Repayment of convertible debt \u2013 related parties" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.", "label": "Repayments of Other Long-Term Debt", "terseLabel": "One-time payment" } } }, "localname": "RepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r46" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Repayment of loans payable \u2013 related parties" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofmakethefollowingpaymentstooxfordTable" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r115", "r202", "r762" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r683", "r698", "r763", "r764" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockExpense": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.", "label": "Restricted Stock or Unit Expense", "terseLabel": "Restricted common stock value" } } }, "localname": "RestrictedStockExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "terseLabel": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings (in Shares)" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "terseLabel": "Grant date value" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r9", "r95", "r187", "r616", "r618", "r669" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r205", "r248", "r249", "r250", "r252", "r258", "r260", "r295", "r476", "r477", "r478", "r499", "r500", "r520", "r613", "r615" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r98", "r99", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r451", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r98", "r99", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r451", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r693" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold", "terseLabel": "Annual base salary" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Aggregate shares (in Shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Exercise price per share (in Dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of anti dilutive common shares" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the equity interest issued or issuable in a business acquisition (or series of individually immaterial business acquisitions) planned, initiated, or completed during the period.", "label": "Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table Text Block]", "terseLabel": "Schedule of accrued issuable equity activity" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccruedIssuableEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of income tax domestic and international components" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtConversionsTextBlock": { "auth_ref": [ "r56", "r57", "r58" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information on an original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. The information may be presented entirely or partially in this block of text or in the associated elements.", "label": "Schedule of Debt Conversions [Table Text Block]", "terseLabel": "Schedule of derivative liabilities" } } }, "localname": "ScheduleOfDebtConversionsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r22", "r91", "r92", "r93", "r94", "r157", "r158", "r160", "r178", "r652", "r654", "r703" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of loans payable of current portion" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/LoansPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of united states federal statutory rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of make the following payments to oxford" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r71", "r73", "r587" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofintangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r71", "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r650" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofgoodwillactivityTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r650", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of goodwill activity" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r161", "r162" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofrelatedpartyloanspayableTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of related party loans payable" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/LoansPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock shares granted and outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablestockoptionsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Schedule of outstanding and exercisable stock options" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r101", "r104", "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of future amortization related to intangible assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IntangibleAssetsandImpairmentofLongLivedAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r2", "r169", "r186" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt", "terseLabel": "Secured convertible promissory note" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotes": { "auth_ref": [ "r172", "r191" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.", "label": "Senior Notes", "terseLabel": "Senior secured convertible promissory note" } } }, "localname": "SeniorNotes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r685", "r686", "r736" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r50" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r666" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Weighted average remaining vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date FV Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofrestrictedstocksharesgrantedandoutstandingTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested Restricted Stock, Unvested Ending", "periodStartLabel": "Unvested Restricted Stock, Unvested Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofrestrictedstocksharesgrantedandoutstandingTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date FV Price, Unvested Ending", "periodStartLabel": "Weighted Average Grant Date FV Price, Unvested Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofrestrictedstocksharesgrantedandoutstandingTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Unvested Restricted Stock, Weighted-average years expected to be recognized over" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofrestrictedstocksharesgrantedandoutstandingTable" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Unvested Restricted Stock, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofrestrictedstocksharesgrantedandoutstandingTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date FV Price, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofrestrictedstocksharesgrantedandoutstandingTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsTable" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Pecentage of salary" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in the number of shares under non-option equity instrument agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease)", "terseLabel": "Purchase of aggregate shares (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of Options, Exercisable ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable (in Dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "terseLabel": "Number of Options, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r738" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Unvested Restricted Stock, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofrestrictedstocksharesgrantedandoutstandingTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of Options, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r111" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Intrinsic Value Outstanding, Ending balance", "periodStartLabel": "Intrinsic Value, Outstanding, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Options, Outstanding ending", "periodStartLabel": "Number of Options, Outstanding beginning", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofantidilutivecommonsharesTable", "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding ending", "periodStartLabel": "Weighted Average Exercise Price, Outstanding beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable", "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r453", "r467", "r468", "r469", "r470", "r473", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablestockoptionsTable", "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablestockoptionsTable", "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablestockoptionsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Warrants Outstanding Exercise Price\t(in Dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablewarrantsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Stock Options Outstanding, Number of Shares" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoutstandingandexercisablestockoptionsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested", "terseLabel": "Intrinsic Value, Exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "periodStartLabel": "Intrinsic Value, Outstanding beginning", "terseLabel": "Intrinsic Value, Outstanding ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Intrinsic Value, Granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofestimatedusingtheblackscholesvaluationmethodassumptionsTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r111" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Intrinsic Value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Life in Years, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Life in Years Outstanding, Beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofwarrantactivityTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Grant Date FV Price, Weighted-average years expected to be recognized over" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofrestrictedstocksharesgrantedandoutstandingTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r465" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Aggregate grant date value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Term (in Years), Outstanding beginning" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Shares of common stock (in Shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Price per share (in Dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTerms": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "Description of the short-term debt arrangement, and disclosures pertaining to the underlying arrangements, including repayment terms, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements.", "label": "Short-Term Debt, Terms", "terseLabel": "Notice period" } } }, "localname": "ShortTermDebtTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "http://180lifesciences.com/role/ScheduleofconvertiblepromissorynotesTable", "http://180lifesciences.com/role/ScheduleofsecuredconvertiblepromissorynotesTable", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConvertibleNotesPayableDetails", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r60", "r239" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r214", "r215", "r216", "r242", "r264", "r265", "r268", "r270", "r274", "r275", "r294", "r332", "r334", "r335", "r336", "r339", "r340", "r369", "r370", "r373", "r377", "r384", "r524", "r639", "r680", "r699", "r708" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r26", "r90", "r205", "r227", "r228", "r229", "r248", "r249", "r250", "r252", "r258", "r260", "r273", "r295", "r386", "r476", "r477", "r478", "r499", "r500", "r520", "r529", "r530", "r531", "r532", "r533", "r535", "r544", "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/DerivativeLiabilitiesDetails", "http://180lifesciences.com/role/ShareholdersEquityType2or3", "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r248", "r249", "r250", "r273", "r586" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r25", "r90", "r91", "r95", "r358" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Shares issued in connection with the repayment of related party loans and convertible notes (Note 12) (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r6", "r7", "r90", "r91", "r95" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Shares, Conversion of Units", "terseLabel": "Shares issued upon conversion of 180 debt (Note 10) (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": { "auth_ref": [ "r6", "r7", "r90", "r95", "r114" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.", "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan", "terseLabel": "Shares issued in connection with the financing, net of financing costs (Note 12) (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Shares issued for professional services to directors (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r6", "r7", "r90", "r95" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Shares issued in connection with the August 2021 Offering, net of financing costs (Note 12) (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Shares issued in connection with December 2022 Offering (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r6", "r7", "r90", "r95" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "terseLabel": "Restricted shares, issued (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "terseLabel": "Adjustments related to reverse stock-split (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r6", "r7", "r90", "r95" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited", "terseLabel": "Shares Cancelled (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r6", "r7", "r90", "r95", "r458" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Shares issued from exercise of July 2022 pre-funded warrants (in Shares)", "verboseLabel": "Number of Options, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofoptionactivityTable", "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments", "terseLabel": "Shares issued upon conversion of KBL debt (Note 10)" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Shares issued for professional services to directors" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r6", "r7", "r90", "r95" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Shares issued in connection with the financing, net of financing costs (Note 12)" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Shares issued in connection with the August 2021 Offering, net of financing costs (Note 12)" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r6", "r7", "r95", "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": { "auth_ref": [ "r110" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, Forfeited", "terseLabel": "Shares Cancelled" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r26", "r90", "r95" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Shares issued from exercise of July 2022 pre-funded warrants" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit.", "label": "Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)", "terseLabel": "Grant value" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r7", "r10", "r11", "r66", "r669", "r701", "r713", "r749" ], "calculation": { "http://180lifesciences.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet", "http://180lifesciences.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r97", "r241", "r370", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r383", "r386", "r519" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r536", "r553" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r536", "r553" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r536", "r553" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r552", "r554" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails", "http://180lifesciences.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.", "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Schedule of valuation deferred tax assets" } } }, "localname": "SummaryOfValuationAllowanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosures of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementaryInsuranceInformationBenefitsClaimsLossesAndSettlementExpense": { "auth_ref": [ "r611" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of insurance benefit, claim, loss and settlement expenses incurred, as disclosed in supplementary insurance information.", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Benefit, Claim, Loss and Settlement Expenses", "terseLabel": "Health insurance expenses" } } }, "localname": "SupplementaryInsuranceInformationBenefitsClaimsLossesAndSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "auth_ref": [ "r118", "r119" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.", "label": "Tax Adjustments, Settlements, and Unusual Provisions", "terseLabel": "True-up to a prior year\u2019s tax return" } } }, "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofvaluationdeferredtaxassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r291", "r292", "r366", "r382", "r518", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r710", "r711", "r712", "r765", "r766", "r767", "r768", "r769", "r770", "r771" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofloanspayableactivityTable" ], "xbrltype": "domainItemType" }, "us-gaap_UnderwritingCommitments": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclose the effect on the financial statements of underwriting commitments open at year-end and subsequently settled.", "label": "Underwriting Commitments", "terseLabel": "Underwriting commitments, description" } } }, "localname": "UnderwritingCommitments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r63", "r64", "r65", "r277", "r278", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r494" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Change in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofincometaxbenefitsprovisionTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValueAddedTaxReceivable": { "auth_ref": [ "r687" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.", "label": "Value Added Tax Receivable", "terseLabel": "Value-added tax receivable" } } }, "localname": "ValueAddedTaxReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ScheduleofprepaidexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r748" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r262", "r270" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average Number of Common Shares Outstanding: (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://180lifesciences.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "40", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28511-109314", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28446-109314", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5708775-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13572-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13587-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=35710175&loc=d3e41687-110959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.16)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "740", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=109255323&loc=d3e66323-112835", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "340", "Topic": "980", "URI": "https://asc.fasb.org/extlink&oid=6066304&loc=d3e44026-110379", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123395306&loc=d3e36975-112693", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14362-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28200-109314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e34017-109320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918703-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919370-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128295416&loc=SL77919784-209982", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column H))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574960-122915", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(4)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(3)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r671": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r672": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r673": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r674": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r675": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r676": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r677": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r678": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r679": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55730-112764", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" }